[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 63 of about 63
1. Jiang X, Ren YP, Lv ZR: Ouabain induces cardiac remodeling in rats independent of blood pressure. Acta Pharmacol Sin; 2007 Mar;28(3):344-52
Hazardous Substances Data Bank. OUABAIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 4 and 6 weeks, echocardiography were performed, hemodynamic parameters were measured by invasive cardiac catheterization, changes in cardiac ultrastructure were analyzed using transmission electron microscopy, the collagen fraction of the left ventricle was assessed with Picrosirius red stain, and RT-PCR was applied to evaluate the mRNA level of myosin heavy chain-alpha and -beta in the left ventricle.
  • Moreover, the cardiac MHC-beta mRNA was upregulated by ouabain treatment, whereas MHC-alpha mRNA was downregulated.
  • [MeSH-minor] Animals. Echocardiography. Glyceraldehyde-3-Phosphate Dehydrogenases / biosynthesis. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Male. Myosin Heavy Chains / biosynthesis. Myosin Heavy Chains / genetics. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302996.001).
  • [ISSN] 1671-4083
  • [Journal-full-title] Acta pharmacologica Sinica
  • [ISO-abbreviation] Acta Pharmacol. Sin.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cardiotonic Agents; 5ACL011P69 / Ouabain; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


2. George TI, Wrede JE, Bangs CD, Cherry AM, Warnke RA, Arber DA: Low-grade B-Cell lymphomas with plasmacytic differentiation lack PAX5 gene rearrangements. J Mol Diagn; 2005 Aug;7(3):346-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade B-Cell lymphomas with plasmacytic differentiation lack PAX5 gene rearrangements.
  • The chromosomal translocation t(9;14)(p13;q32) has been reported in association with lymphoplasmacytic lymphoma (LPL).
  • Although this translocation involving the paired homeobox-5 (PAX5) gene at chromosome band 9p13 and the immunoglobulin heavy chain (IgH) gene at 14q32 has been described in approximately 50% of LPL cases, the actual number of cases studied is quite small.
  • Many of the initial cases associated with t(9;14)(p13;q32) were actually low-grade B-cell lymphomas with plasmacytic differentiation other than LPL.
  • Thus, we analyzed a series of low-grade B-cell lymphomas for PAX5 gene rearrangements.
  • We searched records from the Department of Pathology, Stanford University Medical Center for low-grade B-cell lymphomas, with an emphasis on plasmacytic differentiation, that had available paraffin blocks or frozen tissue.
  • We identified 37 cases, including 13 LPL, 18 marginal zone lymphomas (nodal, extranodal, splenic, and alpha-heavy chain disease), and 6 small lymphocytic lymphomas.
  • All cases failed to demonstrate a PAX5 translocation, indicating that t(9;14)(p13;q32) and other PAX5 translocations are uncommon events in low-grade B-cell lymphomas with plasmacytic differentiation.

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Nov 15;80(10):2594-9 [1384792.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(2):628-32 [2153959.001]
  • [Cites] Int J Hematol. 1998 Feb;67(2):191-8 [9631587.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):691-700 [9722295.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3865-78 [9808580.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):1-9 [11520558.001]
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):543-9 [11601139.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):799-801 [11764065.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2996-3001 [12351413.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):447-54 [15116325.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Jul;22(3):219-23 [3085916.001]
  • [Cites] Jpn J Cancer Res. 1988 Nov;79(11):1193-200 [2852183.001]
  • [Cites] Oncogene. 1989 May;4(5):653-7 [2498807.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4110-7 [8943844.001]
  • (PMID = 16049306.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA34233
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / DNA Probes; 0 / DNA-Binding Proteins; 0 / PAX5 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC1867539
  •  go-up   go-down


3. Vaiphei K, Kumari N, Sinha SK, Dutta U, Nagi B, Joshi K, Singh K: Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease. World J Gastroenterol; 2006 Jun 14;12(22):3602-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease.
  • AIM: To evaluate roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease (IPSID) and to study profiles of kappa (kappa) and lambda (lambda) light chains and IgA heavy chain.
  • METHODS: The study consisted of 11 cases of IPSID and similar number of controls which included 11 of normal intestinal mucosa and 11 of high grade B cell lymphoma of ileum.
  • The parameters analyzed included clinical profiles, biochemical and other laboratory investigations, radiologic and histological findings including immunohistochemistry.
  • RESULTS: All IPSID cases had demonstrable serum IgA heavy chain and heavy mucosal plasma cell infiltration.
  • According to Galian's histological staging, there were 4 patients with stage A and 7 with stage B. kappa and lambda light chains were over-expressed in 7 patients; 1 stage A patient had H pylori-positive active gastritis and eradication of H pylori led to disease remission.
  • Syndecan-1, kappa and lambda light chains and IgA heavy chain showed inverse relationship with bcl6 and p53.
  • CHOP regime was added in 5 patients who developed frank lymphoma.
  • Three died of the disease due to extensive organ infiltration.
  • CONCLUSION: Certain immunomarkers like syndecan-1, kappa and lambda light chains and IgA heavy chain could be of much help in identifying early stage IPSID.
  • Stage B IPSID showed higher expression for bcl6 and p53 than stage A IPSID. bcl6 and p53 expressions correlated with a more advanced disease stage and aggressive tumour behavior.
  • [MeSH-major] DNA-Binding Proteins / genetics. Immunoproliferative Small Intestinal Disease / diagnosis. Immunoproliferative Small Intestinal Disease / genetics. Membrane Glycoproteins / genetics. Proteoglycans / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Case-Control Studies. Disease Progression. Doxycycline / therapeutic use. Endoscopy, Gastrointestinal. Female. Gene Expression Regulation. Helicobacter pylori. Humans. Immunoglobulin alpha-Chains / blood. Immunoglobulin alpha-Chains / genetics. Immunoglobulin kappa-Chains / analysis. Immunoglobulin kappa-Chains / genetics. Immunoglobulin lambda-Chains / analysis. Immunoglobulin lambda-Chains / genetics. Immunohistochemistry. Intestinal Mucosa / chemistry. Intestinal Mucosa / microbiology. Intestinal Mucosa / pathology. Intestine, Small / chemistry. Intestine, Small / microbiology. Intestine, Small / pathology. Male. Middle Aged. Prognosis. Syndecan-1. Syndecans

  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol. 2000 Mar;18(1):1-13 [10797525.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1169-74 [8118801.001]
  • [Cites] Trop Gastroenterol. 2001 Jan-Mar;22(1):14-7 [11398237.001]
  • [Cites] Blood. 2003 Jan 15;101(2):706-10 [12393409.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1220-35 [12393483.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):790-8 [12766583.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1443-8 [12738680.001]
  • [Cites] Indian J Gastroenterol. 1997 Jan;16(1):38 [9167388.001]
  • [Cites] Biochem J. 1997 Oct 1;327 ( Pt 1):1-16 [9355727.001]
  • [Cites] Indian J Gastroenterol. 1998 Jan;17(1):24-7 [9465510.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2679-88 [9531576.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Dec;13(12):1207-11 [9918427.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):403-11 [10208461.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1139-52 [10235185.001]
  • [Cites] J Clin Invest. 1969 Dec;48(12):2374-89 [4982231.001]
  • [Cites] J Oral Pathol Med. 2003 Oct;32(9):513-21 [12969225.001]
  • [Cites] Science. 1968 Dec 20;162(3860):1396-7 [4177362.001]
  • [Cites] Isr J Med Sci. 1969 Mar-Apr;5(2):151-7 [4184815.001]
  • [Cites] Ann N Y Acad Sci. 1971 Dec 31;190:487-500 [5003015.001]
  • [Cites] Br Med J. 1972 Oct 7;4(5831):47 [4562280.001]
  • [Cites] Gut. 1972 Dec;13(12):947-57 [4119805.001]
  • [Cites] Recent Results Cancer Res. 1972;39:193-9 [4664791.001]
  • [Cites] JAMA. 1974 Aug 19;229(8):1103-4 [4407962.001]
  • [Cites] Br J Cancer Suppl. 1975 Mar;2:356-61 [810152.001]
  • [Cites] Cancer. 1977 May;39(5):2081-101 [404026.001]
  • [Cites] Bull World Health Organ. 1976;54(6):615-24 [829415.001]
  • [Cites] Isr J Med Sci. 1979 Feb;15(2):111-23 [112083.001]
  • [Cites] Br Med J. 1980 Apr 12;280(6220):1043-4 [6773611.001]
  • [Cites] N Engl J Med. 1983 Jun 9;308(23):1401-5 [6405275.001]
  • [Cites] Ann N Y Acad Sci. 1983 Jun 30;409:478-85 [6408973.001]
  • [Cites] J Clin Pathol. 1985 Jun;38(6):601-7 [3159757.001]
  • [Cites] J Clin Pathol. 1987 Nov;40(11):1291-7 [3121678.001]
  • [Cites] Cancer. 1988 Apr 15;61(8):1699-706 [3349430.001]
  • [Cites] Gastroenterology. 1988 Oct;95(4):1106-13 [3410224.001]
  • [Cites] Gastroenterology. 1989 Mar;96(3):750-63 [2914638.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 May;25(5):851-6 [2472276.001]
  • [Cites] Am J Surg Pathol. 1989 Dec;13(12):1023-33 [2512818.001]
  • [Cites] Cell Regul. 1989 Nov;1(1):27-35 [2519615.001]
  • [Cites] Blood. 1993 Feb 1;81(3):767-74 [8427968.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):569-70 [8505034.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Intern Med. 1995 Apr;34(4):255-60 [7606093.001]
  • [Cites] Indian J Gastroenterol. 1996 Oct;15(4):135-41 [8916578.001]
  • [Cites] Indian J Gastroenterol. 1996 Apr;15(2):46-8 [8935933.001]
  • [Cites] Lancet. 1997 Jan 4;349(9044):31-2 [8988128.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1815-23 [8114714.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):871-3 [10923927.001]
  • (PMID = 16773719.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Immunoglobulin alpha-Chains; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; 0 / Tumor Suppressor Protein p53; N12000U13O / Doxycycline
  • [Other-IDs] NLM/ PMC4087578
  •  go-up   go-down


Advertisement
4. Wahner-Roedler DL, Kyle RA: Heavy chain diseases. Best Pract Res Clin Haematol; 2005;18(4):729-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heavy chain diseases.
  • Heavy chain diseases (HCDs) are rare B-cell lymphoplasma-cell proliferative disorders characterized by production of truncated monoclonal immunoglobulin heavy chains without associated light chains.
  • HCDs involving the three main immunoglobulin classes have been described; alpha-HCD is the most common and has the most uniform presentation, gamma- and mu-HCDs have variable clinical presentations and histopathologic features.
  • HCDs can be thought of as variant types of non-Hodgkin lymphoma: alpha-HCD presents as an extranodal marginal-zone lymphoma of mucosa-associated lymph-node tissue, gamma-HCD as lymphoplasmacytoid non-Hodgkin lymphoma, and mu-HCD as small lymphocytic non-Hodgkin lymphoma or chronic lymphocytic leukemia.
  • Diagnosis of HCD requires documentation of a deleted immunoglobulin heavy chain without a bound light chain in the serum or urine.
  • Prognosis is variable, and no standardized effective treatment programs are available except for alpha-HCD, which in its early stage may respond to antibiotics.
  • [MeSH-major] Heavy Chain Disease / diagnosis
  • [MeSH-minor] Clinical Laboratory Techniques. Humans. Immunoglobulin Heavy Chains / genetics. Lymphoproliferative Disorders / etiology. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026747.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  • [Number-of-references] 38
  •  go-up   go-down


5. Quinn BA, Hayes MA, Waelchli RO, Kennedy MW, Betteridge KJ: Changes in major proteins in the embryonic capsule during immobilization (fixation) of the conceptus in the third week of pregnancy in the mare. Reproduction; 2007 Jul;134(1):161-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During fixation, beta2M in the capsule underwent limited proteolysis to an approximately 8 kDa form lacking nine amino acids from the N terminus, and was subsequently degraded.
  • During this period, beta2M in the capsule was evidently not part of a complex with major histocompatibility complex class 1 heavy alpha chain bands because these were undetectable in the capsule and uterine lavage.
  • These studies indicate that intact beta2M is a major protein associated with the embryonic capsule before fixation, after which it undergoes limited proteolysis to a truncated approximately 8 kDa form that remains in the capsule after the conceptus is immobilized.
  • [MeSH-minor] Animals. Electrophoresis, Polyacrylamide Gel. Female. Gene Expression. Gestational Age. Histocompatibility Antigens Class I / genetics. Histocompatibility Antigens Class I / metabolism. Immunoblotting. Pregnancy. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Uteroglobin / analysis. Uteroglobin / metabolism. Uterus / chemistry. Uterus / metabolism. Yolk Sac / chemistry. Yolk Sac / metabolism. beta 2-Microglobulin / analysis. beta 2-Microglobulin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641098.001).
  • [ISSN] 1470-1626
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Histocompatibility Antigens Class I; 0 / MHC class I-related chain A; 0 / RNA, Messenger; 0 / beta 2-Microglobulin; 9060-09-7 / Uteroglobin
  •  go-up   go-down


6. Dillmann W: Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev; 2010 Mar;15(2):125-32
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These multiple thyroid hormone effects are largely mediated by the action of nuclear based thyroid hormone receptors (TR) the thyroid hormone receptor alpha and beta.
  • Related to myofibrillar proteins, myosin heavy chain alpha is increased by T3 and MHC beta is decreased.
  • [MeSH-minor] Animals. Humans. Myosin Heavy Chains / metabolism. Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1996 Nov;101(5):461-7 [8948268.001]
  • [Cites] JAMA. 1996 Mar 6;275(9):687-92 [8594265.001]
  • [Cites] J Mol Cell Cardiol. 1998 May;30(5):923-32 [9618233.001]
  • [Cites] Science. 2007 Apr 27;316(5824):575-9 [17379774.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1736-42 [17327384.001]
  • [Cites] Endocrinology. 2007 Jun;148(6):2870-7 [17317766.001]
  • [Cites] Endocrinology. 2007 Oct;148(10):4786-92 [17628010.001]
  • [Cites] Eur J Endocrinol. 2007 Oct;157(4):515-20 [17893267.001]
  • [Cites] J Mol Cell Cardiol. 2007 Oct;43(4):388-403 [17720186.001]
  • [Cites] J Clin Invest. 2008 Mar;118(3):975-83 [18259611.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1351-8 [18171701.001]
  • [Cites] Front Neuroendocrinol. 2008 May;29(2):211-8 [17983645.001]
  • [Cites] Sci Signal. 2008;1(25):pe31 [18577756.001]
  • [Cites] Basic Res Cardiol. 2008 Jul;103(4):308-18 [18274800.001]
  • [Cites] J Am Coll Cardiol. 2008 Sep 30;52(14):1152-9 [18804743.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2008 Nov;295(5):R1425-30 [18784332.001]
  • [Cites] Cardiovasc Pathol. 2009 May-Jun;18(3):183-6 [18402836.001]
  • [Cites] Am J Physiol. 1998 Jul;275(1 Pt 2):H264-73 [9688923.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):623-31 [9927422.001]
  • [Cites] Am J Physiol. 1999 Jun;276(6 Pt 2):H2006-12 [10362681.001]
  • [Cites] Annu Rev Physiol. 2005;67:69-98 [15709953.001]
  • [Cites] Treat Endocrinol. 2004;3(4):233-44 [16026106.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):704-28 [15632316.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2108-18 [16075055.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4926-33 [16081636.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2409-15 [16024568.001]
  • [Cites] MedGenMed. 2005;7(1):74 [16369379.001]
  • [Cites] Mol Cell Endocrinol. 2006 Feb 26;246(1-2):121-7 [16442701.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):6043-8 [16595628.001]
  • [Cites] Curr Heart Fail Rep. 2006 Sep;3(3):114-9 [16914103.001]
  • [Cites] J Gen Intern Med. 2007 Jan;22(1):148-50 [17351857.001]
  • [Cites] Physiol Genomics. 2007 Mar 14;29(1):76-83 [17164392.001]
  • [Cites] Heart Fail Clin. 2005 Jul;1(2):207-18 [17386847.001]
  • [Cites] Heart. 2007 Apr;93(4):483-7 [17005710.001]
  • [Cites] Hypertension. 2007 May;49(5):962-70 [17389260.001]
  • [Cites] Cardiovasc Res. 1999 Aug 1;43(2):382-8 [10536668.001]
  • [Cites] J Mol Cell Cardiol. 2000 Mar;32(3):453-64 [10731444.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Apr;278(4):E738-43 [10751209.001]
  • [Cites] Endocrinology. 2000 Jun;141(6):2139-44 [10830301.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):501-9 [11172193.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):544-50 [11159823.001]
  • [Cites] Circulation. 2001 Feb 27;103(8):1089-94 [11222471.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4761-72 [11416151.001]
  • [Cites] Thyroid. 2002 Apr;12(4):287-93 [12034052.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2461-5 [12072374.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2812-5 [12072417.001]
  • [Cites] Thyroid. 2002 Jun;12(6):501-3 [12165113.001]
  • [Cites] Circulation. 2003 Feb 11;107(5):708-13 [12578873.001]
  • [Cites] Endocr Pract. 2003 Mar-Apr;9(2):140-6 [12917077.001]
  • [Cites] Curr Hypertens Rep. 2003 Dec;5(6):513-20 [14594573.001]
  • [Cites] Recent Prog Horm Res. 2004;59:31-50 [14749496.001]
  • [Cites] Mol Cell Endocrinol. 2003 Dec 31;213(1):1-11 [15062569.001]
  • [Cites] Trends Biochem Sci. 2004 Nov;29(11):609-17 [15501680.001]
  • [Cites] Am J Physiol. 1987 Mar;252(3 Pt 2):H467-73 [3826395.001]
  • [Cites] J Biol Chem. 1991 May 5;266(13):8638-46 [1827123.001]
  • [Cites] Circ Res. 1991 Aug;69(2):266-76 [1830516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5251-5 [1376915.001]
  • [Cites] J Biol Chem. 1995 Jul 7;270(27):16347-54 [7608204.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1522-7 [7477166.001]
  • [Cites] EMBO J. 1997 Jul 16;16(14):4412-20 [9250685.001]
  • (PMID = 19125327.001).
  • [ISSN] 1573-7322
  • [Journal-full-title] Heart failure reviews
  • [ISO-abbreviation] Heart Fail Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Thyroid Hormone; 0 / Thyroid Hormones; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases; EC 3.6.4.1 / Myosin Heavy Chains; SY7Q814VUP / Calcium
  • [Number-of-references] 60
  • [Other-IDs] NLM/ PMC2820695
  •  go-up   go-down


7. Sekine H, Shimizu T, Yang J, Kobayashi E, Okano T: Pulsatile myocardial tubes fabricated with cell sheet engineering. Circulation; 2006 Jul 4;114(1 Suppl):I87-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Neonatal rat cardiomyocyte sheets were sequentially wrapped around a resected adult rat thoracic aorta and transplanted in place of the abdominal aorta of athymic rats (n=17).
  • Finally, when myocardial tubes used for aortic replacement were compared with grafts implanted in the abdominal cavity (n=7), we observed significantly increased tissue thickness, as well as expression of brain natriuretic peptide, myosin heavy chain-alpha, and myosin heavy chain-beta.
  • [MeSH-major] Aorta, Abdominal / surgery. Myocardial Contraction. Myocardium / cytology. Myocytes, Cardiac / transplantation. Tissue Engineering / methods
  • [MeSH-minor] Animals. Animals, Newborn. Aorta, Thoracic / transplantation. Cell Culture Techniques / instrumentation. Cells, Cultured / transplantation. Electrocardiography. Gene Expression Profiling. Microsurgery. Myosin Heavy Chains / biosynthesis. Myosin Heavy Chains / genetics. Natriuretic Peptide, Brain / biosynthesis. Natriuretic Peptide, Brain / genetics. Organ Culture Techniques. Rats. Rats, Nude. Rats, Wistar. Temperature

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820651.001).
  • [ISSN] 1524-4539
  • [Journal-full-title] Circulation
  • [ISO-abbreviation] Circulation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bmyo protein, rat; 0 / natriuretic peptide precursor type B, rat; 114471-18-0 / Natriuretic Peptide, Brain; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


8. Zheng H, Li M, Ren W, Zeng L, Liu HD, Hu D, Deng X, Tang M, Shi Y, Gong J, Cao Y: Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cells. Mol Immunol; 2007 Mar;44(9):2221-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and secretion of immunoglobulin alpha heavy chain with diverse VDJ recombinations by human epithelial cancer cells.
  • Recently, we found the expression of Ig alpha heavy chain in human epithelial cancer cells unexpectedly.
  • Further, the configuration of the Ig heavy chain genomic locus was analyzed in human cancer cells.
  • These provide further proofs for Ig alpha expression.
  • In addition, we found that human cancer cells not only express the protein of Ig alpha chain, but also secrete the protein in secretory IgA (SIgA) pattern.
  • Since IgA is the key immunoglobulin which contributes to local immunity of mucous membrane, the aberrant expression of Ig alpha heavy chain might increase our further comprehension to development and immunity of cancers.
  • [MeSH-major] Epithelial Cells / immunology. Epithelial Cells / pathology. Immunoglobulin A, Secretory / genetics. Immunoglobulin alpha-Chains / genetics. Neoplasms / immunology. Recombination, Genetic. VDJ Exons / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17174398.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Immunoglobulin A, Secretory; 0 / Immunoglobulin alpha-Chains; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RAG2 protein, human; 0 / RNA, Messenger; 128559-51-3 / RAG-1 protein; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


9. Huang YC, Khait L, Birla RK: Modulating the functional performance of bioengineered heart muscle using growth factor stimulation. Ann Biomed Eng; 2008 Aug;36(8):1372-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, at 25 ng/mL, myosin heavy chain alpha and SERCA2 expression increased by 1.3 +/- 0.188 and 1.1 +/- 0.04 fold, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500554.001).
  • [ISSN] 1573-9686
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


10. Dutta U, Udawat H, Noor MT, Sidhu GS, Kochhar R, Vaiphei K, Singh K: Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori. J Gastrointest Cancer; 2010 Sep;41(3):212-5
Hazardous Substances Data Bank. Clarithromycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
  • A 20-year-old male presented with low-grade fever, abdominal pain, anorexia, and weight loss of 4-month duration.
  • Contrast-enhanced computed tomography of the abdomen revealed extensive proximal small-bowel thickening with mesenteric lymphadenopathy.
  • Upper gastrointestinal endoscopy and enteroscopy revealed thickening of folds with multiple small superficial ulceration involving antrum, duodenum, and jejunum.
  • The duodenal and jejunal biopsy was suggestive of immunoproliferative small intestinal disease, stage 0 (Salem) or stage A (Galian).
  • He underwent H. pylori eradication following which he had significant clinical improvement; repeat evaluation at 6 months showed dramatic improvement in his clinical, radiological, and histological parameters.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Helicobacter Infections / complications. Immunoproliferative Small Intestinal Disease / drug therapy. Immunoproliferative Small Intestinal Disease / microbiology

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • Hazardous Substances Data Bank. TINIDAZOLE .
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20300878.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Bacterial Agents; 0 / Organometallic Compounds; 033KF7V46H / Tinidazole; 0K5C5T2QPG / Lansoprazole; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; HS813P8QPX / bismuth tripotassium dicitrate; KG60484QX9 / Omeprazole; N12000U13O / Doxycycline
  •  go-up   go-down


11. Zhou H, Hickford JG, Fang Q: Identification of allelic polymorphism in the caprine IGHA gene. Dev Comp Immunol; 2006;30(9):741-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Variation in the immunoglobulin heavy alpha chain (IGHA) constant region has been reported in a number of species.
  • The variation reported here may affect the structure of the hinge and hence the function of IgA.
  • [MeSH-major] Goats / genetics. Goats / immunology. Immunoglobulin alpha-Chains / genetics
  • [MeSH-minor] Alleles. Amino Acid Sequence. Animals. Base Sequence. DNA / chemistry. DNA / genetics. Hinge Exons. Molecular Sequence Data. Polymerase Chain Reaction / veterinary. Polymorphism, Single-Stranded Conformational. Sequence Alignment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343618.001).
  • [ISSN] 0145-305X
  • [Journal-full-title] Developmental and comparative immunology
  • [ISO-abbreviation] Dev. Comp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin alpha-Chains; 9007-49-2 / DNA
  •  go-up   go-down


12. Ishikawa T, Sakakibara H, Oiwa K: The architecture of outer dynein arms in situ. J Mol Biol; 2007 May 18;368(5):1249-58

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Outer dynein arms, the force generators for axonemal motion, form arrays on microtubule doublets in situ, although they are bouquet-like complexes with separated heads of multiple heavy chains when isolated in vitro.
  • To understand how the three heavy chains are folded in the array, we reconstructed the detailed 3D structure of outer dynein arms of Chlamydomonas flagella in situ by electron cryo-tomography and single-particle averaging.
  • The three AAA rings of heavy chains, seen as stacked plates, are connected in a striking manner on microtubule doublets.
  • The tail of the alpha-heavy chain, identified by analyzing the oda11 mutant, which lacks alpha-heavy chain, extends from the AAA ring tilted toward the tip of the axoneme and towards the inside of the axoneme at 50 degrees , suggesting a three-dimensional power stroke.
  • The neighboring outer dynein arms are connected through two filamentous structures: one at the exterior of the axoneme and the other through the alpha-tail.
  • Although the beta-tail seems to merge with the alpha-tail at the internal side of the axoneme, the gamma-tail is likely to extend at the exterior of the axoneme and join the AAA ring.
  • This suggests that the fold and function of gamma-heavy chain are different from those of alpha and beta-chains.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391698.001).
  • [ISSN] 0022-2836
  • [Journal-full-title] Journal of molecular biology
  • [ISO-abbreviation] J. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.6.4.2 / Dyneins
  •  go-up   go-down


13. Ben Ammar A, Cheikh I, Jouini M, Belkahla N, Fadhel SF, Hager O, Maamouri N, Chaabouni H, Ben Safta Z, Haouet S: [Alpha heavy chain disease. A Tunisian case]. Tunis Med; 2006 Sep;84(9):581-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alpha heavy chain disease. A Tunisian case].
  • [Transliterated title] Maladie des chaines lourdes alpha. A propos d'un cas tunisien.
  • Alpha heavy chain disease is a rare affection in the West and reported mainly in developing countries with the improvement of hygienic conditions, the disease become rare in Tunisia, the last case was reported in 1991.
  • The aim of the study is to report a new Tunisian case and to describe clinical, endoscopical and histological characteristics of the disease.
  • The diagnosis of alpha heavy chain disease was confirmed by histological examination of the resected intestine after surgery for intestinal obstruction.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / diagnosis
  • [MeSH-minor] Adult. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263208.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


14. Parfenov AI, Krums LM, Sivash ES, Tsaregorodtseva TM, Poleva NI, Ruchkina IN, Sabel'nikova EA, Chikunova BZ: [Algorithm for diagnosis of small intestinal diseases]. Ter Arkh; 2008;80(4):46-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Algorithm for diagnosis of small intestinal diseases].
  • AIM: To review diagnostic approaches in chronic diseases of the small intestine.
  • MATERIAL AND METHODS: A total of 1096 patients with chronic diseases of the small intestine were admitted to the clinic of the Central Research Institute of Gastroenterological Diseases in 1987-2006.
  • RESULTS: Most of the patients (90.5%) had celiac disease, hypolactasia and other types of disaccharidase deficiency, yersiniosis ileitis, Krohn's disease, postresection syndrome of a short small intestine, mesenterial ischemia and endocrine enteropathy.
  • Rare diseases (general variable hypogammaglobulinemia, lymphoma, Wipple's disease and diverticulosis of the small intestine) were diagnosed in 5.8% cases.
  • Primary amyloidosis of the small intestine, eosinophilic gastroenteritis, arteriomesenterial obstruction, primary intestinal pseudoobstruction, hypogammaglobulinemic spru, primary intestinal lymphangiectasia, tuberculosis, total polyposis, Peutz-Eggers and Cronkhite-Canada syndromes, collagenic sprue, erosive-ulcerative jejunoileitis, adenocarcinoma and heavy alpha-chain disease were detected in 3.7% examinees.
  • These diseases were encountered in one to 5 cases for the latest 20 years.
  • CONCLUSION: Clinical diagnosis of small intestinal diseases is based on the syndromes of chronic diarrhea, defective absorption, enteral protein loss, small intestinal obstruction and intestinal hemorrhage.
  • Differential diagnosis of the nosological entities employs x-ray, endoscopic, histological, immunological and other methods.
  • Most of the small intestinal diseases including rare can be diagnosed in any gastroentorological department.
  • [MeSH-major] Algorithms. Endoscopy, Gastrointestinal / methods. Immunologic Tests / methods. Intestinal Diseases / diagnosis. Intestine, Small. Radiography, Abdominal / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491580.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


15. Zhou H, Hickford JG, Fang Q: Polymorphism of the IGHA gene in sheep. Immunogenetics; 2005 Jul;57(6):453-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, variation in the immunoglobulin heavy alpha chain constant gene (IGHA) of sheep was investigated by amplification of a fragment that included the hinge coding sequence, followed by single-strand conformational polymorphism (SSCP) analysis and DNA sequencing.
  • [MeSH-major] Immunoglobulin alpha-Chains / genetics. Polymorphism, Single-Stranded Conformational. Sheep / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025324.001).
  • [ISSN] 0093-7711
  • [Journal-full-title] Immunogenetics
  • [ISO-abbreviation] Immunogenetics
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY956424/ AY956425/ AY956426
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Immunoglobulin alpha-Chains
  •  go-up   go-down


16. Mielcarek-Kuchta D, Olofsson J, Golusinski W: Laminin expression in advanced laryngeal squamous cell carcinoma does not correlate to neck metastases. Eur Arch Otorhinolaryngol; 2008 Oct;265(10):1257-61
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laminins are a family of glycoproteins that consist of one heavy alpha chain and two light beta and gamma chains.
  • The study was carried out on 70 patients with squamous cell carcinoma of the larynx treated at the ENT Department University of Medical Sciences in Poznań.
  • The clinical data consisted of sex, age, stage of the tumor, and histological and immunohistochemical studies.
  • The patients with advanced clinical disease dominated in our material.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516614.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin
  •  go-up   go-down


17. Furuta A, Yagi T, Yanagisawa HA, Higuchi H, Kamiya R: Systematic comparison of in vitro motile properties between Chlamydomonas wild-type and mutant outer arm dyneins each lacking one of the three heavy chains. J Biol Chem; 2009 Feb 27;284(9):5927-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic comparison of in vitro motile properties between Chlamydomonas wild-type and mutant outer arm dyneins each lacking one of the three heavy chains.
  • Outer arm dynein (OAD) of cilia and flagella contains two or three distinct heavy chains, each having a motor function.
  • To elucidate their functional difference, we compared the in vitro motile properties of Chlamydomonas wild-type OAD containing the alpha, beta, and gamma heavy chains and three kinds of mutant OADs, each lacking one of the three heavy chains.
  • Wild-type OAD displayed microtubule gliding in the presence of ATP and ADP, with a maximal velocity of 5.0 mum/s, which is approximately 1/4 of the microtubule sliding velocity in the axoneme.
  • The absence of the beta heavy chain lowered both the gliding velocity and ATPase activity, whereas the absence of the gamma heavy chain increased both activities.
  • Strikingly, the absence of the alpha heavy chain lowered the gliding velocity but increased the ATPase activity.
  • Thus, the three heavy chains are likely to play distinct roles and regulate each other to achieve coordinated force production.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19124458.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Subunits; EC 3.6.4.2 / Dyneins
  •  go-up   go-down


18. Economidou I, Manousos ON, Triantafillidis JK, Vaslamatzis MM, Zafiropoulou R, Papadakis T: Immunoproliferative small intestinal disease in Greece: presentation of 13 cases including two from Albania. Eur J Gastroenterol Hepatol; 2006 Sep;18(9):1029-38
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease in Greece: presentation of 13 cases including two from Albania.
  • OBJECTIVES: Immunoproliferative small intestinal disease (IPSID) represents a spectrum of clinicopathological entities including alpha-chain disease and other types of lymphoplasmacytic proliferations of the lamina propria of the small intestine, presenting with severe malabsorption.
  • IPSID has been described mainly in the Mediterranean, Middle East, and African countries.
  • METHODS: Current immunological and immunohistochemical methods for the detection of alpha heavy chains and the presence of clonality have been used to study 13 cases of IPSID diagnosed in Greece, two of whom were Albanian residents.
  • RESULTS: The patients were categorized in three subgroups of IPSID: alpha-chain disease (n=8), non-alpha chain disease with other monoclonal immunoglobulins (n=3), and polyclonal 'non-malignant' IPSID (n=2).
  • In several patients the disease had unusual features, and this in some cases delayed the diagnosis.
  • Patients with stage C disease had a short survival, whereas two patients with stage A alpha-chain disease responded to treatment with cyclophosphamide, vincristine and prednisolone, and cyclophosphamide, doxorubicine, vincristine and prednisolone, respectively, have a disease-free long survival of 35 and 12 years, and appear to be cured.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / diagnosis

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894320.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


19. Lampton PW, Goldstein CY, Warner CM: The role of tapasin in MHC class I protein trafficking in embryos and T cells. J Reprod Immunol; 2008 Jun;78(1):28-39
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similar in structure to MHC class Ia proteins, Qa-2 protein is a trimer of the alpha (heavy) chain, beta(2) microglobulin and a bound peptide.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1996 Aug;5(2):103-14 [8769474.001]
  • [Cites] J Immunol. 1994 Jun 1;152(11):5268-74 [8189046.001]
  • [Cites] Am J Reprod Immunol. 1998 Sep;40(3):165-71 [9764360.001]
  • [Cites] Mol Hum Reprod. 1998 Oct;4(10):966-71 [9809678.001]
  • [Cites] Reprod Fertil Dev. 2004;16(7):729-41 [15740696.001]
  • [Cites] Immunol Rev. 2005 Oct;207:89-99 [16181329.001]
  • [Cites] Immunol Rev. 2005 Oct;207:145-57 [16181333.001]
  • [Cites] J Cell Sci. 2006 Feb 15;119(Pt 4):615-23 [16467570.001]
  • [Cites] J Physiol. 2006 Feb 15;571(Pt 1):211-20 [16269433.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16412-7 [17056715.001]
  • [Cites] Hum Immunol. 2007 Jan;68(1):1-11 [17207707.001]
  • [Cites] Biol Reprod. 2007 Aug;77(2):274-9 [17442853.001]
  • [Cites] Transplantation. 1999 Dec 15;68(11):1790-9 [10609958.001]
  • [Cites] J Reprod Immunol. 2000 Feb;46(1):1-15 [10708239.001]
  • [Cites] Immunity. 2000 Aug;13(2):213-22 [10981964.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1095-9 [11221838.001]
  • [Cites] Nat Immunol. 2000 Sep;1(3):234-8 [10973281.001]
  • [Cites] Trends Immunol. 2001 Apr;22(4):194-9 [11274924.001]
  • [Cites] Curr Top Dev Biol. 2001;52:151-92 [11529429.001]
  • [Cites] Immunogenetics. 2001 Aug;53(6):455-67 [11685456.001]
  • [Cites] Structure. 2001 Dec;9(12):1213-24 [11738047.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2200-11 [11859106.001]
  • [Cites] Immunity. 2002 Apr;16(4):509-20 [11970875.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Hum Reprod. 2002 Nov;17(11):2938-47 [12407053.001]
  • [Cites] Nature. 2002 Dec 5;420(6915):520-62 [12466850.001]
  • [Cites] J Immunol. 2003 Jan 15;170(2):961-8 [12517962.001]
  • [Cites] Annu Rev Immunol. 2003;21:629-57 [12500978.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14337-45 [12582157.001]
  • [Cites] J Immunol. 2003 May 1;170(9):4515-23 [12707328.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):e154 [14654707.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Feb 14;1:27 [12646049.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4394-401 [15383569.001]
  • [Cites] Biol Reprod. 1987 Apr;36(3):611-6 [3593833.001]
  • [Cites] J Reprod Immunol. 1991 Apr;19(3):303-13 [1865393.001]
  • [Cites] Nature. 1992 Feb 13;355(6361):644-6 [1538752.001]
  • [Cites] Nature. 1993 Feb 18;361(6413):642-4 [8437623.001]
  • [Cites] Biol Reprod. 1993 May;48(5):1082-7 [8481472.001]
  • [Cites] J Biol Chem. 1993 Aug 25;268(24):17959-66 [8349678.001]
  • [Cites] J Immunol. 1993 Nov 15;151(10):5338-47 [8228229.001]
  • [Cites] J Exp Med. 1994 Feb 1;179(2):579-88 [8294869.001]
  • [Cites] J Immunol. 1997 Sep 15;159(6):2771-81 [9300698.001]
  • (PMID = 18061684.001).
  • [ISSN] 0165-0378
  • [Journal-full-title] Journal of reproductive immunology
  • [ISO-abbreviation] J. Reprod. Immunol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD039215-05; United States / NICHD NIH HHS / HD / R01 HD039215; United States / NICHD NIH HHS / HD / HD39215; United States / NICHD NIH HHS / HD / R01 HD039215-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / Molecular Chaperones; 0 / Peptides; 0 / Q surface antigens; 0 / Tap1 protein, mouse; 0 / beta 2-Microglobulin
  • [Other-IDs] NLM/ NIHMS51787; NLM/ PMC2459227
  •  go-up   go-down


20. Lin YS, Zhou H, Forrest RH, Frampton CM, Hickford JG: Association between variation in faecal egg count for a mixed field-challenge of nematode parasites and IGHA gene polymorphism. Vet Immunol Immunopathol; 2009 Apr 15;128(4):389-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Research has shown that variation in ovine immunoglobulin A (IgA) levels are associated with reduced faecal egg counts (FECs) in sheep hosting gastro-intestinal (GI) parasites.
  • Variation in the constant region of the ovine IgA heavy alpha chain gene (IGHA) may result in structurally and functionally different IgA molecules and may consequently lead to variation in the IgA response to parasitisation.
  • However, when the data was split into predominant challenge type groups, associations were detected.
  • [MeSH-major] Gastrointestinal Diseases / veterinary. Immunoglobulin A / genetics. Nematoda / growth & development. Nematode Infections / veterinary. Sheep Diseases / immunology. Sheep Diseases / parasitology
  • [MeSH-minor] Alleles. Animals. DNA, Helminth / chemistry. DNA, Helminth / genetics. Feces / parasitology. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Heavy Chains / immunology. Male. Parasite Egg Count / veterinary. Polymerase Chain Reaction / veterinary. Polymorphism, Single-Stranded Conformational. Sheep

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19150137.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Helminth; 0 / Immunoglobulin A; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


21. Pai RK, Snider WK, Starkey CR, Viswanatha D, Foucar MK, Wilson CS: Nonsecretory variant of immunoproliferative small intestinal disease: a case report with pathologic, immunophenotypic, and molecular findings. Arch Pathol Lab Med; 2005 Nov;129(11):1487-90
Hazardous Substances Data Bank. OMEPRAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsecretory variant of immunoproliferative small intestinal disease: a case report with pathologic, immunophenotypic, and molecular findings.
  • We report a case of the nonsecretory variant of immunoproliferative small intestinal disease involving the distal small bowel and the mesenteric and retroperitoneal lymph nodes in a 19-year-old woman from Mexico.
  • This variant extranodal marginal zone B-cell lymphoma appeared similar in the different sites of involvement, with more interspersed large cells and greater plasmacytic differentiation present in intestinal specimens.
  • Characteristic lymphoepithelial lesions and follicular colonization were seen in intestinal and lymph node sections, respectively.
  • The neoplastic B cells were cytoplasmic immunoglobulin (Ig) A heavy-chain restricted and lacked surface and cytoplasmic light-chain expression by flow cytometric analysis.
  • Molecular studies showed absence of immunoglobulin heavy-chain (IgH) gene rearrangement, with a nonfunctional clonotypic rearrangement of the kappa light-chain gene.
  • This case highlights the role for kappa light-chain gene evaluation in immunoproliferative small intestinal disease, because IgH gene rearrangement analysis is often negative.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / pathology. Lymph Nodes / pathology. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles. Adult. Amoxicillin / therapeutic use. Anti-Bacterial Agents / therapeutic use. Benzimidazoles / therapeutic use. Drug Therapy, Combination. Female. Gene Rearrangement, B-Lymphocyte, Light Chain / genetics. Humans. Immunophenotyping. Intestine, Small / pathology. Mesentery. Metronidazole / therapeutic use. Omeprazole / analogs & derivatives. Omeprazole / therapeutic use. Retroperitoneal Space. Sulfoxides / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PANTOPRAZOLE .
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253033.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Bacterial Agents; 0 / Benzimidazoles; 0 / Sulfoxides; 140QMO216E / Metronidazole; 804826J2HU / Amoxicillin; D8TST4O562 / pantoprazole; KG60484QX9 / Omeprazole
  •  go-up   go-down


22. Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H, Takami T, Moriwaki H: Immunoproliferative small intestinal disease with protein loss complicated with duodenal T cell lymphoma during progression. Intern Med; 2008;47(4):299-303
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease with protein loss complicated with duodenal T cell lymphoma during progression.
  • A 52-year-old man was admitted to our hospital in October 2001 with abdominal pain.
  • Abdominal X-ray indicated a diagnosis of ileus.
  • Histopathological and immunological examination resulted in a diagnosis of immunoproliferative small intestinal disease (IPSID).
  • He was diagnosed with relapsed IPSID and salvage chemotherapy was started.
  • Immunohistochemical staining revealed T-cell lymphoma.
  • [MeSH-major] Duodenal Neoplasms / etiology. Immunoproliferative Small Intestinal Disease / complications. Lymphoma, T-Cell / etiology
  • [MeSH-minor] Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277034.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proteins
  •  go-up   go-down


23. Salem PA, Estephan FF: Immunoproliferative small intestinal disease: current concepts. Cancer J; 2005 Sep-Oct;11(5):374-82
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for immunoproliferative small intestinal disease .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease: current concepts.
  • Immunoproliferative small intestinal disease is a distinctive lymphoproliferative disorder.
  • Among these disorders, it is the only disease associated with a specific and characteristic abnormal protein, and also an identifiable, at least in some patients, early phase with a benign-looking histo-pathologic expression.
  • Whether the disease at this stage is malignant or not is not known.
  • This observation is significant and raises the question of chemoprevention in lymphomas.
  • In contrast to primary nonimmunoproliferative small intestinal lymphomas, in which the pathology in the intestine is usually focal and involving specific segments of the intestine and leaving the segments between the involved areas free of disease, the pathology in immunoproliferative small intestinal disease is diffuse, with a mucosal cellular infiltrate involving large segments of the intestine and sometimes the entire length of the intestine, thus producing malabsorption.
  • Preliminary recent epidemiological data have shown a decrease in the incidence of this disease in endemic areas, and therefore environmental factors are suspected to play a major role in its pathogenesis.
  • Additional research is indicated not only to understand this specific lymphoproliferative disorder but also to understand lymphomas in general.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16259867.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


24. Liu Z, Takazaki H, Nakazawa Y, Sakato M, Yagi T, Yasunaga T, King SM, Kamiya R: Partially functional outer-arm dynein in a novel Chlamydomonas mutant expressing a truncated gamma heavy chain. Eukaryot Cell; 2008 Jul;7(7):1136-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partially functional outer-arm dynein in a novel Chlamydomonas mutant expressing a truncated gamma heavy chain.
  • The outer dynein arm of Chlamydomonas flagella contains three heavy chains (alpha, beta, and gamma), each of which exhibits motor activity.
  • Here we report the isolation of a novel mutant, oda2-t, whose gamma heavy chain is truncated at about 30% of the sequence.
  • While the previously isolated gamma chain mutant oda2 lacks the entire outer arm, oda2-t retains outer arms that contain alpha and beta heavy chains, suggesting that the N-terminal sequence (corresponding to the tail region) is necessary and sufficient for stable outer-arm assembly.
  • Thin-section electron microscopy and image analysis localize the gamma heavy chain to a basal region of the outer-arm image in the axonemal cross section.
  • The motility of oda2-t is lower than that of the wild type and oda11 (lacking the alpha heavy chain) but higher than that of oda2 and oda4-s7 (lacking the motor domain of the beta heavy chain).
  • Thus, the outer-arm dynein lacking the gamma heavy-chain motor domain is partially functional.
  • The availability of mutants lacking individual heavy chains should greatly facilitate studies on the structure and function of the outer-arm dynein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 1978 Oct;33:235-53 [31367.001]
  • [Cites] J Biol Chem. 1979 Jan 10;254(1):187-96 [214440.001]
  • [Cites] J Cell Biol. 1980 Aug;86(2):446-55 [6447155.001]
  • [Cites] Cell. 1982 Jan;28(1):115-24 [6461414.001]
  • [Cites] J Cell Biol. 1982 Dec;95(3):798-815 [6218174.001]
  • [Cites] J Cell Biol. 1983 Mar;96(3):669-78 [6220019.001]
  • [Cites] J Cell Biol. 1983 May;96(5):1480-5 [6221024.001]
  • [Cites] J Cell Biol. 1983 Sep;97(3):902-8 [6224802.001]
  • [Cites] J Biol Chem. 1984 Oct 10;259(19):12072-80 [6237107.001]
  • [Cites] J Mol Biol. 1984 Dec 25;180(4):1083-118 [6241263.001]
  • [Cites] J Cell Biol. 1985 Apr;100(4):1228-34 [3156867.001]
  • [Cites] J Cell Sci. 1985 Mar;74:181-91 [4030906.001]
  • [Cites] Anal Biochem. 1986 Feb 1;152(2):376-85 [3963370.001]
  • [Cites] J Mol Biol. 1987 Apr 5;194(3):481-94 [2957507.001]
  • [Cites] J Cell Biol. 1988 Nov;107(5):1793-7 [2972730.001]
  • [Cites] J Cell Biol. 1988 Nov;107(5):1799-808 [2460468.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):8998-9002 [2461560.001]
  • [Cites] J Cell Biol. 1988 Dec;107(6 Pt 1):2253-8 [2974040.001]
  • [Cites] Eur J Biochem. 1990 Apr 30;189(2):441-6 [2140096.001]
  • [Cites] J Cell Biol. 1991 May;113(3):615-22 [1673127.001]
  • [Cites] J Biochem. 1992 Jun;111(6):758-62 [1386849.001]
  • [Cites] J Cell Biol. 1992 Sep;118(5):1189-200 [1387406.001]
  • [Cites] J Cell Biol. 1993 Aug;122(3):653-61 [8335691.001]
  • [Cites] Genetics. 1993 Oct;135(2):375-84 [8244002.001]
  • [Cites] J Cell Sci. 1994 Mar;107 ( Pt 3):497-506 [7516341.001]
  • [Cites] J Cell Biol. 1996 Feb;132(3):359-70 [8636214.001]
  • [Cites] J Cell Sci. 1995 Dec;108 ( Pt 12):3757-64 [8719882.001]
  • [Cites] J Struct Biol. 1996 Jan-Feb;116(1):155-60 [8742738.001]
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 2):1853-65 [8991096.001]
  • [Cites] J Cell Biol. 1997 Jun 2;137(5):1081-90 [9166408.001]
  • [Cites] Cell Motil Cytoskeleton. 1997;37(2):120-6 [9186009.001]
  • [Cites] Cell Motil Cytoskeleton. 1997;37(4):338-45 [9258506.001]
  • [Cites] J Cell Sci. 1998 May;111 ( Pt 9):1155-64 [9547292.001]
  • [Cites] Biochemistry. 1999 Jun 1;38(22):7253-64 [10353837.001]
  • [Cites] Mol Biol Cell. 2005 Dec;16(12):5661-74 [16195342.001]
  • [Cites] J Biol Chem. 2005 Dec 16;280(50):41412-20 [16236707.001]
  • [Cites] J Cell Sci. 2006 Aug 15;119(Pt 16):3443-55 [16882690.001]
  • [Cites] Science. 2006 Aug 18;313(5789):944-8 [16917055.001]
  • [Cites] J Cell Biol. 2007 Apr 23;177(2):243-52 [17438074.001]
  • [Cites] J Cell Sci. 2007 May 1;120(Pt 9):1513-20 [17405810.001]
  • [Cites] J Mol Biol. 2007 May 18;368(5):1249-58 [17391698.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Jul;46(3):190-9 [10913966.001]
  • [Cites] Mol Biol Cell. 2000 Jul;11(7):2297-313 [10888669.001]
  • [Cites] Mol Biol Cell. 2007 Sep;18(9):3620-34 [17634291.001]
  • [Cites] Methods. 2000 Dec;22(4):383-7 [11133244.001]
  • [Cites] Int Rev Cytol. 2002;219:115-55 [12211628.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43571-9 [12923201.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 Mar;57(3):186-96 [14743351.001]
  • [Cites] J Struct Biol. 2004 Apr-May;146(1-2):58-71 [15037237.001]
  • [Cites] J Biol Chem. 1979 Apr 25;254(8):3091-9 [429335.001]
  • (PMID = 18487347.001).
  • [ISSN] 1535-9786
  • [Journal-full-title] Eukaryotic cell
  • [ISO-abbreviation] Eukaryotic Cell
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM051293; United States / NIGMS NIH HHS / GM / GM51293
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Subunits; 0 / Protozoan Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.4.2 / Dyneins
  • [Other-IDs] NLM/ PMC2446680
  •  go-up   go-down


25. Wilson TA, Nicolosi RJ, Kotyla T, Sundram K, Kritchevsky D: Different palm oil preparations reduce plasma cholesterol concentrations and aortic cholesterol accumulation compared to coconut oil in hypercholesterolemic hamsters. J Nutr Biochem; 2005 Oct;16(10):633-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hamsters were fed a chow-based hypercholesterolemic diet (HCD) containing 10% coconut oil and 0.1% cholesterol for 2 weeks at which time they were bled after an overnight fast and segregated into four groups of 12 with similar plasma cholesterol concentrations.
  • Group 1 continued on the HCD, Group 2 was fed the HCD containing 10% RPO in place of coconut oil, Group 3 was fed the HCD containing 10% RBD-PO in place of coconut oil and Group 4 was fed the HCD with 10% reconstituted RBD-PO for an additional 10 weeks.
  • The plasma gamma-tocopherol concentrations were higher in the coconut oil-fed hamsters compared to the hamsters fed the RPO (60%), RBD-PO (42%) and the reconstituted RBD-PO (49%), while for plasma alpha-tocopherol concentrations, the coconut oil-fed hamsters were significantly higher than only the RPO-fed hamsters (21%).
  • [MeSH-minor] Animals. Cholesterol, HDL / blood. Chromatography, High Pressure Liquid. Cricetinae. Fatty Acids / analysis. Feces / chemistry. Lipid Peroxides / blood. Mesocricetus. Sterols / analysis. Vitamin E / analysis. Vitamin E / blood. alpha-Tocopherol / blood. gamma-Tocopherol / blood

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. VITAMIN E .
  • Hazardous Substances Data Bank. Coconut oil .
  • Hazardous Substances Data Bank. Palm oil (from fruit) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16081272.001).
  • [ISSN] 0955-2863
  • [Journal-full-title] The Journal of nutritional biochemistry
  • [ISO-abbreviation] J. Nutr. Biochem.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL 00734
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholesterol, HDL; 0 / Dietary Fats, Unsaturated; 0 / Fatty Acids; 0 / Lipid Peroxides; 0 / Plant Oils; 0 / Sterols; 1406-18-4 / Vitamin E; 8001-31-8 / coconut oil; 8002-75-3 / palm oil; 8EF1Z1238F / gamma-Tocopherol; 97C5T2UQ7J / Cholesterol; H4N855PNZ1 / alpha-Tocopherol
  •  go-up   go-down


26. Busnelli M, Froio A, Bacci ML, Giunti M, Cerrito MG, Giovannoni R, Forni M, Gentilini F, Scagliarini A, Deleo G, Benatti C, Leone BE, Biasi GM, Lavitrano M: Pathogenetic role of hypercholesterolemia in a novel preclinical model of vascular injury in pigs. Atherosclerosis; 2009 Dec;207(2):384-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Most strategies against intimal hyperplasia developed in several preclinical models failed in terms of clinical application, often due to a discrepancy between animal and human disease.
  • METHODS: Pigs were fed with standard (SD, n=7) or high-cholesterol diet (HCD, n=7) for 120 days.
  • HCD significantly increased the degree of stenosis (48+/-3% vs. 13+/-4%, p=0.001), with induction of cell proliferation, matrix deposition, TGF-beta1/TGFbetaRII and MMP2 expression and reduction of collagen.
  • The reduced expression of the protective gene heme oxygenase-1 and inducible-nitric oxide synthase in HCD was associated to a systemic inflammation with a significant increase in circulating leukocytes, serum IFN-gamma and TNF-alpha and a local inflammatory response with an increase of CD3-positive cell infiltrates.
  • New therapeutical strategies to prevent restenosis can be tested in this preclinical hypercholesterolemic model resembling human disease.
  • [MeSH-minor] Animals. Antigens, CD3 / metabolism. Carotid Arteries / metabolism. Carotid Arteries / pathology. Cholesterol, LDL / blood. Collagen Type I / metabolism. Disease Models, Animal. Female. Heme Oxygenase-1 / metabolism. Hyperplasia. Inflammation Mediators / blood. Interferon-gamma / blood. Leukocytes / immunology. Matrix Metalloproteinase 2 / metabolism. Nitric Oxide Synthase Type II / metabolism. Protein-Serine-Threonine Kinases / metabolism. Receptors, Transforming Growth Factor beta / metabolism. Severity of Illness Index. Swine. Transforming Growth Factor beta1 / metabolism. Tumor Necrosis Factor-alpha / blood

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540496.001).
  • [ISSN] 1879-1484
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Cholesterol, LDL; 0 / Collagen Type I; 0 / Inflammation Mediators; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.3 / Heme Oxygenase-1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


27. Nagi B, Rana SS, Kochhar R, Bhasin DK: Sonoenteroclysis: a new technique for the diagnosis of small bowel diseases. Abdom Imaging; 2006 Jul-Aug;31(4):417-24
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonoenteroclysis: a new technique for the diagnosis of small bowel diseases.
  • BACKGROUND: Radiologic evaluation of small bowel is usually done by barium examination, which involves considerable radiation exposure.
  • A new sonographic method, sonoenteroclysis, is a promising technique for diagnosing small intestinal disorders.
  • METHODS: Forty-five consecutive patients with suspected small bowel disorder were studied.
  • All patients underwent abdominal ultrasound before and after infusion of an isotonic nonabsorbable electrolyte solution containing polyethylene glycol through a nasojejunal tube (modified Billbao Dotter tube), and images at various levels were obtained.
  • Small bowel wall thickness, luminal narrowing, intestinal dilatation, peristalsis, and extraintestinal complications were noted.
  • RESULTS: Satisfactory distention of the intestinal lumen was obtained with sequential visualization of jejunoileal loops in 34.4 +/- 18.4 min.
  • Of 45 patients, 10 showed normal small bowel on sonoenteroclysis and barium enteroclysis.
  • The remaining 35 patients showed abnormalities in the form of strictures, matted bowel loops, dilated loops, thickened folds, deformed ileocecal junction, mass lesions, etc., on sonoenteroclysis and barium enteroclysis.
  • These were diagnosed subsequently as cases of tuberculosis (n = 23), celiac disease (n = 6), adenocarcinoma (n = 2), leiomyoma (n = 2), Immunoproliferative small intestinal disease (n = 1), and segmental enteritis (n = 1).
  • CONCLUSIONS: The diagnostic accuracy of sonoenteroclysis for detecting small bowel lesions is comparable to that of barium enteroclysis.
  • This new, widely available, inexpensive, and undemanding technique can be used as an initial investigation in the evaluation of patients with small bowel disorders.
  • [MeSH-major] Intestinal Diseases / ultrasonography. Intestine, Small / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447095.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


28. Hills CE, Bland R, Bennett J, Ronco PM, Squires PE: High glucose up-regulates ENaC and SGK1 expression in HCD-cells. Cell Physiol Biochem; 2006;18(6):337-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High glucose up-regulates ENaC and SGK1 expression in HCD-cells.
  • METHODS: Here we present RT-PCR, western blot and immunocytochemistry data confirming mRNA and protein expression of the serum and glucocorticoid inducible kinase (SGK1) and the alpha conducting subunit of the epithelial sodium channel (ENaC) in a model in vitro system of the human cortical collecting duct (HCD).
  • We examined changes in expression of these elements in response to glucose challenge, designed to mimic hyperglycaemia associated with type 2 diabetes mellitus.
  • [MeSH-minor] Blotting, Western. Cells, Cultured. Diabetes Mellitus / metabolism. Humans. Hyperglycemia / etiology. Hyperglycemia / metabolism. Hypertension / etiology. Ionomycin / pharmacology. RNA, Messenger / analysis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sodium / metabolism. Transforming Growth Factor beta1 / genetics. Transforming Growth Factor beta1 / metabolism. Transforming Growth Factor beta1 / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17170520.001).
  • [ISSN] 1015-8987
  • [Journal-full-title] Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • [ISO-abbreviation] Cell. Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Epithelial Sodium Channels; 0 / Immediate-Early Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta1; 56092-81-0 / Ionomycin; 9NEZ333N27 / Sodium; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / serum-glucocorticoid regulated kinase; IY9XDZ35W2 / Glucose
  •  go-up   go-down


29. Miron I, Mihăilă D, Aprodu G, Miron L, Plămădeală P, Moisă SM: Immunoproliferative small intestinal disease versus colonic monoblastic sarcoma in a 2-year-old boy. Rom J Morphol Embryol; 2009;50(4):733-8
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease versus colonic monoblastic sarcoma in a 2-year-old boy.
  • The authors present a case of colonic monoblastic sarcoma, previously treated for other digestive abnormalities (malabsorbtion, Hirschprung's disease).
  • Important similitudes with immunoproliferative small intestinal disease (IPSID) lymphoma were demonstrated for this patient (male, 2-year-old).
  • Some particularities of this case are the young age and the extremely rapid development of the malignant disease in a patient with no previous signs of acute non-lymphoblastic leukemia.
  • The initial diagnosis was of malabsorbtion syndrome, based on the clinical exam at presentation, and then the patient was thought to have a form of Hirschprung's disease, due to a functional intestinal disorder (slow transit).
  • After the necropsy, pathologists diagnosed an immunoproliferative small intestinal disease, and four years later, they performed a more appropriate pathological exam, which explained better clinical symptoms associated to this complex case.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Immunoproliferative Small Intestinal Disease / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Hirschsprung Disease / diagnosis. Humans. Malabsorption Syndromes / diagnosis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942975.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


30. Al-Saleem T, Al-Mondhiry H: Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood; 2005 Mar 15;105(6):2274-80
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for immunoproliferative small intestinal disease .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms.
  • Immunoproliferative small intestinal disease (IPSID) was recently added to the growing list of infectious pathogen-associated human lymphomas.
  • IPSID is a variant of the B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), which involves mainly the proximal small intestine resulting in malabsorption, diarrhea, and abdominal pain.
  • Geographically, IPSID is most prevalent in the Middle East and Africa.
  • IPSID lymphomas reveal excessive plasma cell differentiation and produce truncated alpha heavy chain proteins lacking the light chains as well as the first constant domain.
  • The corresponding mRNA lacks the variable heavy chain (V(H)) and the constant heavy chain 1 (C(H)1) sequences and contains deletions as well as insertions of unknown origin.
  • Cytogenetic studies demonstrated clonal rearrangements involving predominantly the heavy and light chain genes, including t(9;14) translocation involving the PAX5 gene.
  • Early-stage IPSID responds to antibiotics (30%-70% complete remission).
  • Most untreated IPSID patients progress to lymphoplasmacytic and immunoblastic lymphoma invading the intestinal wall and mesenteric lymph nodes, and may metastasize to a distant organ.
  • IPSID lymphoma shares clinical, morphologic, and molecular features with MALT lymphoma, lymphoplasmacytic lymphoma, and plasma cell neoplasms.
  • [MeSH-major] Campylobacter Infections. Campylobacter jejuni. Immunoproliferative Small Intestinal Disease. Lymphoma, B-Cell, Marginal Zone. Plasma Cells / immunology
  • [MeSH-minor] Adolescent. Adult. Africa. B-Cell-Specific Activator Protein / genetics. B-Cell-Specific Activator Protein / immunology. Child. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 9 / genetics. Chromosomes, Human, Pair 9 / immunology. Female. Humans. Immunoglobulin Light Chains / genetics. Immunoglobulin Light Chains / immunology. Immunoglobulin Variable Region / genetics. Immunoglobulin Variable Region / immunology. Immunoglobulin alpha-Chains / genetics. Immunoglobulin alpha-Chains / immunology. Intestine, Small / immunology. Intestine, Small / pathology. Lymph Nodes / immunology. Lymph Nodes / pathology. Male. Mesentery / immunology. Mesentery / pathology. Middle East. Sequence Deletion / genetics. Sequence Deletion / immunology. Translocation, Genetic / genetics. Translocation, Genetic / immunology

  • MedlinePlus Health Information. consumer health - Campylobacter Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542584.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Variable Region; 0 / Immunoglobulin alpha-Chains; 0 / PAX5 protein, human
  • [Number-of-references] 78
  •  go-up   go-down


31. Miller CP, Valliant-Saunders K, Blau CA: Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression. Transl Oncol; 2010 Jun 01;3(3):176-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EPO receptor (EPOR) messenger RNA (mRNA) was detectable in both B16F10 tumors and mammary tumors from MMTV-PyMT mice but was 0.12 +/- 0.02% and 1.3 +/- 0.91% of the EPOR mRNA level in murine erythroid HCD-57 cells, respectively.
  • B16F10 tumor growth rates in mice treated for 3 weeks with 30 microg/kg per week of darbepoetin alpha, 0.41 inverse days (range, 0.05-0.69 inverse days; n = 16), were similar to tumor growth rates observed in mice treated with PBS, 0.42 inverse days (range, 0.10-0.69 inverse days; n = 17).
  • In contrast, darbepoetin alpha raised hematocrit levels to 0.593 (maximum, 0.729) compared with 0.448 (maximum, 0.532) in PBS-treated mice (P = .0004).
  • In MMTV-PyMT mice, the weights of tumor-bearing mammary glands in mice treated for 6 weeks with 30 microg/kg per week of darbepoetin alpha, 3.37 g (range, 1.94-5.81 g; n = 27), did not significantly differ from the weights in PBS-treated mice, 3.76 g (range, 2.30-6.33 g; n = 26).
  • In contrast, darbepoetin alpha raised hematocrit levels to 0.441 (maximum, 0.606) compared with 0.405 (maximum, 0.492) in PBS-treated mice (P = .05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3520-5 [9270023.001]
  • [Cites] Blood. 1991 Mar 15;77(6):1228-33 [1705834.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1255-60 [14575968.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):2113-26 [14578209.001]
  • [Cites] Carcinogenesis. 2003 Jun;24(6):1021-9 [12807756.001]
  • [Cites] Genomics. 2001 Jun 15;74(3):253-61 [11414753.001]
  • [Cites] Breast Cancer Res. 2000;2(3):211-6 [11250712.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):836-43 [11259101.001]
  • [Cites] Lancet. 2009 May 2;373(9674):1532-42 [19410717.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e36 [19040789.001]
  • [Cites] Neoplasia. 2008 Sep;10(9):932-9 [18714393.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4685-90 [18676735.001]
  • [Cites] JAMA. 2008 Feb 27;299(8):914-24 [18314434.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1040-50 [18227526.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):477-88 [17582631.001]
  • [Cites] PLoS One. 2007;2(6):e549 [17579721.001]
  • [Cites] Transgenic Res. 2007 Apr;16(2):193-201 [17206489.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1027-32 [17312332.001]
  • [Cites] Acta Otolaryngol. 2006 May;126(5):545-7 [16698707.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5960-72 [16087945.001]
  • [Cites] Proc Soc Exp Biol Med. 1962 Jul;110:436-40 [14463220.001]
  • [Cites] Zentralbl Pathol. 1992 Sep;138(4):266-70 [1420106.001]
  • (PMID = 20563259.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA135357
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2887647
  •  go-up   go-down


32. Boja ES, Phillips D, French SA, Harris RA, Balaban RS: Quantitative mitochondrial phosphoproteomics using iTRAQ on an LTQ-Orbitrap with high energy collision dissociation. J Proteome Res; 2009 Oct;8(10):4665-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the use of iTRAQ labeling and mass spectrometry on an LTQ-Orbitrap with HCD capability, we assessed relative changes in protein phosphorylation in the mitochondria upon physiological perturbation.
  • As a reference reaction, we monitored the well-characterized regulation of pyruvate dehydrogenase (PDH) activity via phosphorylation/dephosphorylation by pyruvate dehydrogenase kinase/pyruvate dehydrogenase phosphatase in response to dichloroacetate, de-energization and Ca2+.
  • Dephosphorylation at Ser292 (i.e., the inhibitory site) with DCA correlated with an activation of PDH activity as previously reported, consistent with our de-energization data.
  • (1) BCKDH-E1alpha subunit increased phosphorylation at Ser337 with DCA and de-energization;.
  • (3) ATP synthase F1 complex alpha subunit and (4) mitofilin dephosphorylated at Ser65 and Ser264 upon de-energization.
  • This screening validated the iTRAQ/HCD technology as a method for functional quantitation of mitochondrial protein phosphorylation as well as providing insight into the regulation of mitochondria via phosphorylation.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. DICHLOROACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 1):C900-9 [9730975.001]
  • [Cites] Mol Cell Biochem. 1995 Aug-Sep;149-150:203-12 [8569730.001]
  • [Cites] Biochemistry. 2006 Feb 28;45(8):2524-36 [16489745.001]
  • [Cites] Biochem Soc Trans. 2006 Apr;34(Pt 2):217-22 [16545080.001]
  • [Cites] J Biol Chem. 2006 Sep 15;281(37):27643-52 [16847060.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1488-93 [17242355.001]
  • [Cites] Mol Cell Proteomics. 2007 Apr;6(4):669-76 [17208939.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1896-906 [17761666.001]
  • [Cites] J Proteome Res. 2007 Dec;6(12):4684-9 [17929885.001]
  • [Cites] FEBS Lett. 2008 Apr 2;582(7):1104-10 [18331841.001]
  • [Cites] Mol Cell Proteomics. 2008 May;7(5):971-80 [18212344.001]
  • [Cites] Mol Cell Proteomics. 2008 Jul;7(7):1331-48 [18388127.001]
  • [Cites] J Am Soc Mass Spectrom. 2008 Sep;19(9):1255-62 [18620867.001]
  • [Cites] Cardiovasc Res. 2008 Oct 1;80(1):20-9 [18558627.001]
  • [Cites] Mol Cell Proteomics. 2008 Sep;7(9):1702-13 [18511480.001]
  • [Cites] Mol Cell Proteomics. 2008 Sep;7(9):1714-24 [18541608.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Oct-Nov;60(13-14):1478-87 [18647626.001]
  • [Cites] Nat Protoc. 2008;3(10):1630-8 [18833199.001]
  • [Cites] J Proteome Res. 2009 Jun;8(6):2679-95 [19351177.001]
  • [Cites] Cell. 2000 Jan 7;100(1):113-27 [10647936.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8389-96 [10722671.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E127-30 [11988757.001]
  • [Cites] J Mol Cell Cardiol. 2002 Oct;34(10):1259-71 [12392982.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1912-34 [12471243.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34189-202 [12799386.001]
  • [Cites] Electrophoresis. 2004 Aug;25(15):2526-32 [15300772.001]
  • [Cites] Biochem Biophys Res Commun. 1974 Aug 19;59(4):1341-8 [4370205.001]
  • [Cites] Biochem J. 1974 Sep;141(3):761-74 [4478069.001]
  • [Cites] Biochem J. 1978 Feb 1;169(2):433-5 [204298.001]
  • [Cites] Biochemistry. 1978 Jun 13;17(12):2364-70 [678513.001]
  • [Cites] Biochem J. 1978 Aug 1;173(2):659-68 [697742.001]
  • [Cites] Biochemistry. 1982 Aug 31;21(18):4259-65 [6812622.001]
  • [Cites] Biochem J. 1984 Aug 1;221(3):593-9 [6477487.001]
  • [Cites] Arch Biochem Biophys. 1986 Jan;244(1):187-201 [3947057.001]
  • [Cites] Ann N Y Acad Sci. 1989;573:218-29 [2699399.001]
  • [Cites] Biochim Biophys Acta. 1990 May 8;1038(3):360-6 [2340295.001]
  • [Cites] Protein Expr Purif. 1991 Aug;2(4):278-86 [1821799.001]
  • [Cites] Adv Enzyme Regul. 1995;35:147-62 [7572341.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • (PMID = 19694452.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 HL004601-20
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitochondrial Proteins; 0 / Phosphopeptides; 0 / Phosphoproteins; 9LSH52S3LQ / Dichloroacetic Acid; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.2 / pyruvate dehydrogenase (acetyl-transferring) kinase; EC 3.1.3.43 / Pyruvate Dehydrogenase (Lipoamide)-Phosphatase; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS135287; NLM/ PMC2768122
  •  go-up   go-down


33. Mutanabbi M, Noor MK, Helal MA, Rahman MH: Coeliac disease. Mymensingh Med J; 2009 Jan;18(1 Suppl):S136-139
MedlinePlus Health Information. consumer health - Celiac Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coeliac disease.
  • Coeliac disease is an autoimmune disorder of the small bowel that occurs in genetically predisposed people of all ages from middle infancy.
  • Coeliac disease is caused by a reaction to gliadin, a gluten protein found in wheat.
  • Upon exposure to gliadin, the enzyme tissue transglutaminase modifies the protein and the immune system cross reacts with the bowel tissue, causing an inflammatory reaction that leads to flattening of the lining of the small intestine, which interferes with the absorption of nutrient's.
  • He had loose mucoid stool, abdominal distension, bloating and history of loss of weight for two years.
  • Along with the routine examinations foecal fat estimation, MT, USG of whole abdomen, Barium follow through, endoscopic biopsy and tissue transglutaminage IgA autoantibody was done.
  • Histopathological report was in favour of immunoproliferative small intestinal disease.
  • Tissue transglutaminage IgA autoantibody was in higher level though done in a gluten free state.
  • Symptoms of diarrhoea, abdominal distention and bloatedness gradually decreased.
  • For patients presenting with alteration of bowel habit, abdominal distension, bloating and history of weight loss for long time, the importance of considering coeliac diseases as a differential diagnosis cannot be overemphasized.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377424.001).
  • [ISSN] 1022-4742
  • [Journal-full-title] Mymensingh medical journal : MMJ
  • [ISO-abbreviation] Mymensingh Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Immunoglobulin A; 9007-90-3 / Gliadin; EC 2.3.2.13 / Transglutaminases
  •  go-up   go-down


34. Shaye OS, Levine AM: Marginal zone lymphoma. J Natl Compr Canc Netw; 2006 Mar;4(3):311-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone lymphoma.
  • Marginal zone lymphomas (MZLs) comprise 3 distinct entities: extranodal MZL of mucosa-associated lymphoid tissue (MALT), splenic MZL, and nodal MZL.
  • Gastric MALT lymphoma is the most common extranodal MZL and often develops as a result of chronic Helicobacter pylori gastritis.
  • Antigen-driven lymphomatous disease can also be seen in the association of Borrelia burgdorferi with MALT lymphoma of the skin, Chlamydia psittaci with MALT lymphoma of the ocular adnexa, Campylobacter jejuni with immunoproliferative disease of the small intestine, and hepatitis C with splenic MZL.
  • This article discusses the pathogenesis and clinical features of MZL and the treatment options available to patients.
  • [MeSH-major] Helicobacter Infections / complications. Lymphoma / diagnosis. Lymphoma / therapy. Splenic Neoplasms. Stomach Neoplasms
  • [MeSH-minor] Chronic Disease. Gastritis / microbiology. Helicobacter pylori. Humans. Lymphoma, B-Cell, Marginal Zone

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16507274.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 73
  •  go-up   go-down


35. Amom Z, Zakaria Z, Mohamed J, Azlan A, Bahari H, Taufik Hidayat Baharuldin M, Aris Moklas M, Osman K, Asmawi Z, Kamal Nik Hassan M: Lipid lowering effect of antioxidant alpha-lipoic Acid in experimental atherosclerosis. J Clin Biochem Nutr; 2008 Sep;43(2):88-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid lowering effect of antioxidant alpha-lipoic Acid in experimental atherosclerosis.
  • In the present study, a protective activity of alpha-lipoic acid; a metabolic antioxidant in hypercholesterolemic-induced animals was investigated.
  • Eighteen adult male New Zealand White (NZW) rabbit were segregated into three groups labelled as group N, HCD and ALA (n = 6).
  • Group N (normal control) was fed with normal chow, the rest (HCD and ALA) were fed with 100 g/head/day of 1% cholesterol rich diet to induce hypercholesterolemia.
  • Four point two mg/body weight of alpha lipoic acid was concomintantly supplemented to the ALA group.
  • The plasma total cholesterol (TC) and low density lipoprotein (LDL) levels were found to be significantly low in ALA group compared to that of the HCD group (p<0.05).
  • Similarly, low level of MDA (p<0.05) in ALA group was observed compared to that of the HCD group showing a significant reduction of lipid peroxidation activity.
  • Histomorphometric intimal lesion analysis of the aorta showing less of atheromatous plaque formation in alpha lipoic acid supplemented group (p<0.05) compared to HCD group.
  • These findings suggested that alpha lipoic acid posses a dual lipid lowering and anti-atherosclerotic properties indicated with low plasma TC and LDL levels and reduction of athero-lesion formation in hypercholesterolemic-induced rabbits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cardiol. 2000 Sep;15(5):355-63 [11128189.001]
  • [Cites] Atherosclerosis. 2001 May;156(1):91-101 [11369001.001]
  • [Cites] Free Radic Biol Med. 1999 Nov;27(9-10):1114-21 [10569644.001]
  • [Cites] Free Radic Biol Med. 2006 Jan 1;40(1):3-12 [16337874.001]
  • [Cites] Free Radic Biol Med. 2005 May 15;38(10):1278-95 [15855047.001]
  • [Cites] J Mol Cell Cardiol. 2005 Mar;38(3):445-51 [15733904.001]
  • [Cites] Atherosclerosis. 2005 Mar;179(1):87-95 [15721013.001]
  • [Cites] J Lipid Res. 1998 Jun;39(6):1141-51 [9643345.001]
  • [Cites] J Lipid Res. 1998 May;39(5):1079-90 [9610776.001]
  • [Cites] Biofactors. 1998;7(3):263-7 [9568264.001]
  • [Cites] JAMA. 1998 May 27;279(20):1615-22 [9613910.001]
  • [Cites] Free Radic Biol Med. 1997;22(1-2):359-78 [8958163.001]
  • [Cites] Diabetes Care. 1995 Aug;18(8):1160-7 [7587852.001]
  • [Cites] Circulation. 1995 May 1;91(9):2488-96 [7729036.001]
  • [Cites] Free Radic Biol Med. 1995 Aug;19(2):227-50 [7649494.001]
  • [Cites] Cell Mol Biol Lett. 2004;9(3):511-8 [15332127.001]
  • [Cites] Free Radic Biol Med. 2003 Mar 15;34(6):746-52 [12633751.001]
  • [Cites] J Agric Food Chem. 2002 Oct 9;50(21):6102-8 [12358487.001]
  • [Cites] Curr Mol Med. 2001 Dec;1(6):633-53 [11899253.001]
  • [Cites] Free Radic Biol Med. 2000 Jun 15;28(12):1685-96 [10946210.001]
  • (PMID = 18818758.001).
  • [ISSN] 0912-0009
  • [Journal-full-title] Journal of clinical biochemistry and nutrition
  • [ISO-abbreviation] J Clin Biochem Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2533724
  • [Keywords] NOTNLM ; alpha lipoic acid / antioxidant / atherosclerosis / intimal lesion / lipid peroxidation
  •  go-up   go-down


36. Yao R, Cheng X, Liao YH, Chen Y, Xie JJ, Yu X, Ding YJ, Tang TT: Molecular mechanisms of felodipine suppressing atherosclerosis in high-cholesterol-diet apolipoprotein E-knockout mice. J Cardiovasc Pharmacol; 2008 Feb;51(2):188-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was undertaken to investigate the potential effects and molecular mechanisms of the CCB felodipine on the process of atherosclerosis in high-cholesterol-diet (HCD) apolipoprotein E-knockout (ApoE KO) mice.
  • Adult male ApoE KO mice were given a normal diet (ND) or HCD and were randomized to no treatment or felodipine (5 mg / kg per day for 12 weeks).
  • The ApoE KO mice with HCD were associated with a marked increase in plasma lipid levels, atherosclerotic lesion area, and the expressions of NADPH oxidase subunits (p47 and Rac-1), nuclear factor-kappaB (NF-kappaB) in nucleus, phosphor-inhibitors of kappaB (p-IkappaB), tumor necrosis-alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1), and vascular cell-adhesion molecule-1 (VCAM-1).
  • These changes were suppressed in mice that were treated with felodipine (5 mg/kg per day for 12 weeks) concomitant with HCD administration, with no significant change in systolic blood pressure and plasma lipid levels.
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Chemokine CCL2 / metabolism. Diet, Atherogenic. Lipids / blood. Male. Mice. Mice, Knockout. NADPH Oxidase / metabolism. NF-kappa B / metabolism. Oxidative Stress / drug effects. Random Allocation. Tumor Necrosis Factor-alpha / metabolism. Vascular Cell Adhesion Molecule-1 / metabolism

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287887.001).
  • [ISSN] 0160-2446
  • [Journal-full-title] Journal of cardiovascular pharmacology
  • [ISO-abbreviation] J. Cardiovasc. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Calcium Channel Blockers; 0 / Chemokine CCL2; 0 / Cholesterol, Dietary; 0 / Lipids; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Cell Adhesion Molecule-1; EC 1.6.3.1 / NADPH Oxidase; OL961R6O2C / Felodipine
  •  go-up   go-down


37. Zhang Y, Dong XL, Leung PC, Wong MS: Differential mRNA expression profiles in proximal tibia of aged rats in response to ovariectomy and low-Ca diet. Bone; 2009 Jan;44(1):46-52
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aged (11 months old) Sprague-Dawley rats were subjected to bilateral ovariectomy or sham-operation and fed with diets containing different dietary Ca content (LCD, 0.1% Ca or HCD, 1.2% Ca) for 12 weeks.
  • Ovariectomy increased serum N-telopeptides of bone type I collagen (NTx) levels in aged rats fed with HCD (P<0.05).
  • In addition, ovariectomy reduced BMD and predicted bone strength of tibial proximal metaphysis in aged rats fed with either LCD or HCD.
  • Ovariectomy promoted the mRNA expression of alpha-1 type I collagen (COL), osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligand (RANKL); and inhibited the mRNA expression of cathepsin K and matrix metalloproteinase-9 (MMP-9) in the proximal tibia of aged rats.

  • MedlinePlus Health Information. consumer health - Calcium.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18848653.001).
  • [ISSN] 1873-2763
  • [Journal-full-title] Bone
  • [ISO-abbreviation] Bone
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Calcium, Dietary; 0 / Osteoprotegerin; 0 / RANK Ligand; 0 / RNA, Messenger
  •  go-up   go-down


38. Holaska JM, Wilson KL: An emerin "proteome": purification of distinct emerin-containing complexes from HeLa cells suggests molecular basis for diverse roles including gene regulation, mRNA splicing, signaling, mechanosensing, and nuclear architecture. Biochemistry; 2007 Jul 31;46(30):8897-908
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These proteins were identified by mass spectrometry as nuclear alphaII-spectrin, nonmuscle myosin heavy chain alpha, Lmo7 (a predicted transcription regulator; reported separately), nuclear myosin I, beta-actin (reported separately), calponin 3, and SIKE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO Rep. 2005 May;6(5):445-51 [15832170.001]
  • [Cites] Biochem Cell Biol. 2005 Aug;83(4):405-17 [16094444.001]
  • [Cites] J Cell Biol. 2005 Aug 29;170(5):781-91 [16115958.001]
  • [Cites] J Cell Sci. 2005 Sep 1;118(Pt 17):4017-25 [16129885.001]
  • [Cites] J Proteome Res. 2005 Sep-Oct;4(5):1661-71 [16212419.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):39925-33 [16204256.001]
  • [Cites] Development. 2005 Dec;132(24):5565-75 [16280346.001]
  • [Cites] Anticancer Drugs. 2006 Jan;17(1):13-20 [16317285.001]
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):32904-8 [10551855.001]
  • [Cites] Gene. 1999 Oct 18;239(1):15-27 [10571030.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):217-26 [10607832.001]
  • [Cites] J Mol Histol. 2005 Jun;36(5):337-44 [16283426.001]
  • [Cites] Trends Cell Biol. 2005 Dec;15(12):651-8 [16243528.001]
  • [Cites] EMBO J. 2005 Dec 7;24(23):4018-28 [16281057.001]
  • [Cites] J Biol Chem. 2005 Dec 16;280(50):41207-12 [16230350.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):42252-62 [16203725.001]
  • [Cites] Exp Cell Res. 2006 Feb 15;312(4):478-87 [16337940.001]
  • [Cites] Nature. 2005 Dec 22;438(7071):1116-22 [16222246.001]
  • [Cites] J Cell Sci. 2006 Jan 15;119(Pt 2):239-49 [16410549.001]
  • [Cites] Genes Dev. 2006 Feb 15;20(4):486-500 [16481476.001]
  • [Cites] Mol Biol Cell. 2006 Mar;17(3):1154-63 [16371512.001]
  • [Cites] Brain. 2006 Apr;129(Pt 4):996-1013 [16478798.001]
  • [Cites] Curr Biol. 2006 Apr 18;16(8):825-31 [16631592.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):203-13 [16725345.001]
  • [Cites] FEBS J. 2006 Jul;273(14):3204-15 [16857009.001]
  • [Cites] EMBO J. 2006 Jul 26;25(14):3275-85 [16858403.001]
  • [Cites] Curr Opin Cell Biol. 2002 Jun;14(3):357-64 [12067659.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):575-85 [12154369.001]
  • [Cites] FEBS Lett. 2002 Aug 14;525(1-3):135-40 [12163176.001]
  • [Cites] J Cell Biol. 2002 Aug 5;158(3):475-85 [12163470.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):43288-300 [12215455.001]
  • [Cites] Acta Haematol. 2002;108(4):210-8 [12432217.001]
  • [Cites] Dev Cell. 2002 Nov;3(5):659-71 [12431373.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 17;300(3):679-85 [12507503.001]
  • [Cites] J Cell Sci. 2003 Mar 1;116(Pt 5):823-35 [12571280.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):6969-75 [12493765.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1336-46 [12628926.001]
  • [Cites] Muscle Nerve. 2003 Apr;27(4):393-406 [12661041.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14394-400 [12566455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4598-603 [12684533.001]
  • [Cites] J Neurol Sci. 2003 Jun 15;210(1-2):47-51 [12736087.001]
  • [Cites] EMBO J. 2003 May 15;22(10):2324-33 [12743027.001]
  • [Cites] Eur J Biochem. 2003 Jun;270(11):2459-66 [12755701.001]
  • [Cites] Hum Mol Genet. 2003 Jun 1;12(11):1301-12 [12761045.001]
  • [Cites] Neuromuscul Disord. 2003 Aug;13(6):508-15 [12899879.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1380-2 [12958361.001]
  • [Cites] Annu Rev Biochem. 2003;72:573-608 [14527325.001]
  • [Cites] EMBO J. 2003 Nov 3;22(21):5928-40 [14592989.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):97-105 [14743216.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2006 Jul;288(7):676-80 [16761279.001]
  • [Cites] Biochem Cell Biol. 2006 Aug;84(4):418-26 [16936815.001]
  • [Cites] FEBS J. 2006 Oct;273(19):4562-75 [16972941.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Oct;7(10):782-8 [16926857.001]
  • [Cites] Hum Mol Genet. 2006 Dec 1;15(23):3459-72 [17067998.001]
  • [Cites] Trends Cell Biol. 2007 Apr;17(4):202-8 [17320395.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14525-35 [17355960.001]
  • [Cites] Exp Cell Res. 2007 Aug 1;313(13):2845-57 [17462627.001]
  • [Cites] Eur J Biochem. 2004 Mar;271(5):1035-45 [15009215.001]
  • [Cites] Curr Opin Cell Biol. 2004 Feb;16(1):61-7 [15037306.001]
  • [Cites] Curr Opin Cell Biol. 2004 Feb;16(1):73-9 [15037308.001]
  • [Cites] Trends Cell Biol. 2004 May;14(5):261-6 [15130582.001]
  • [Cites] Mol Cell. 2004 Jun 4;14(5):685-91 [15175163.001]
  • [Cites] Genome Res. 2004 Jul;14(7):1315-23 [15231747.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30856-64 [15123707.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):37175-84 [15220328.001]
  • [Cites] Curr Biol. 2004 Aug 24;14(16):1436-50 [15324660.001]
  • [Cites] PLoS Biol. 2004 Sep;2(9):E231 [15328537.001]
  • [Cites] Prog Clin Biol Res. 1990;327:141-8 [2138789.001]
  • [Cites] J Biol Chem. 1990 Jun 15;265(17):10148-55 [2161834.001]
  • [Cites] J Biochem. 1990 Nov;108(5):835-8 [2150518.001]
  • [Cites] Biochem J. 1991 Nov 15;280 ( Pt 1):33-8 [1835840.001]
  • [Cites] Genetics. 1993 Feb;133(2):361-73 [8382178.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Dec 5;217(1):238-44 [8526917.001]
  • [Cites] Nat Genet. 1996 Mar;12(3):254-9 [8589715.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):14653-6 [8663349.001]
  • [Cites] Neuromuscul Disord. 2000 Jun;10(4-5):228-32 [10838246.001]
  • [Cites] J Biol Chem. 2000 Jun 23;275(25):18871-8 [10770926.001]
  • [Cites] Mol Cell. 2000 Apr;5(4):671-82 [10882103.001]
  • [Cites] Science. 2000 Oct 13;290(5490):337-41 [11030652.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):377-81 [11099047.001]
  • [Cites] J Biol Chem. 2000 Dec 22;275(51):40463-70 [11013263.001]
  • [Cites] Trends Biochem Sci. 2001 Jan;26(1):41-7 [11165516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1454-8 [11171972.001]
  • [Cites] J Cell Biol. 2001 Mar 5;152(5):895-910 [11238447.001]
  • [Cites] Curr Opin Cell Biol. 2001 Jun;13(3):274-80 [11343897.001]
  • [Cites] Biochemistry. 2001 Jun 19;40(24):7025-34 [11401546.001]
  • [Cites] FEBS Lett. 2001 Jul 20;501(2-3):171-6 [11470279.001]
  • [Cites] EMBO J. 2001 Aug 15;20(16):4399-407 [11500367.001]
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):1019-30 [11535620.001]
  • [Cites] Am J Hum Genet. 2001 Nov;69(5):1033-45 [11590545.001]
  • [Cites] J Cell Sci. 2001 Sep;114(Pt 18):3297-307 [11591818.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):90-4 [11752412.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 24):4567-73 [11792821.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 24):4575-85 [11792822.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2080-3 [11859155.001]
  • [Cites] Mol Cell. 2002 Mar;9(3):611-23 [11931768.001]
  • [Cites] Annu Rev Biochem. 2002;71:755-81 [12045110.001]
  • [Cites] J Cell Biol. 2002 Jun 10;157(6):929-39 [12045181.001]
  • [Cites] Cell. 1997 May 2;89(3):357-64 [9150135.001]
  • [Cites] J Biol Chem. 1997 Jul 4;272(27):17176-81 [9202039.001]
  • [Cites] J Biol Chem. 1997 Nov 7;272(45):28695-703 [9353338.001]
  • [Cites] Trends Biochem Sci. 1998 May;23(5):174-8 [9612081.001]
  • [Cites] Mol Cell. 1998 Dec;2(6):851-61 [9885572.001]
  • [Cites] Nature. 1999 Apr 29;398(6730):824-8 [10235266.001]
  • [Cites] J Cell Sci. 1999 Aug;112 ( Pt 15):2571-82 [10393813.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9873-8 [10449787.001]
  • [Cites] Nat Cell Biol. 2004 Dec;6(12):1165-72 [15558034.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):512-22 [15601870.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):21-31 [15688064.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):254-64 [15696166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3290-5 [15728376.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1698-710 [15674337.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13863-70 [15681850.001]
  • (PMID = 17620012.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / F32 GM067397-02; United States / NIGMS NIH HHS / GM / R01 GM048646-07; United States / NCRR NIH HHS / RR / 1S10-RR14702; United States / NIGMS NIH HHS / GM / GM048646-07; United States / NIGMS NIH HHS / GM / GM067397-02; United States / NIGMS NIH HHS / GM / F32GM067397; United States / NIGMS NIH HHS / GM / F32 GM067397; United States / NIGMS NIH HHS / GM / R01 GM048646; United States / NIGMS NIH HHS / GM / R01GM48646
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Chromatin; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Multiprotein Complexes; 0 / Nuclear Matrix-Associated Proteins; 0 / Nuclear Proteins; 0 / Proteome; 0 / Recombinant Fusion Proteins; 0 / Transcription Factors; 0 / emerin
  • [Other-IDs] NLM/ NIHMS62576; NLM/ PMC2635128
  •  go-up   go-down


39. Yang DJ, Chang YY, Hsu CL, Liu CW, Lin YL, Lin YH, Liu KC, Chen YC: Antiobesity and hypolipidemic effects of polyphenol-rich longan (Dimocarpus longans Lour.) flower water extract in hypercaloric-dietary rats. J Agric Food Chem; 2010 Feb 10;58(3):2020-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (2) hypercaloric diet and pure water (HCD + NDW);.
  • (3) HCD and 1.25% (w/v) LFWE (HCD + 1.25% LFWE);.
  • (4) HCD and 2.5% (w/v) LFWE (HCD + 2.5% LFWE) for 9 weeks.
  • Body weight, size of epididymal fat, serum triglyceride level and atherogenic index, and hepatic lipids were decreased (p < 0.05) in HCD rats by drinking 2.5% LFWE which may result from downregulated (p < 0.05) pancreatic lipase activity, and sterol regulatory element binding protein-1c (SREBP-1c) and fatty acid synthase (FAS) gene expressions, as well as upregulated (p < 0.05) LDL receptor (LDLR) and peroxisome proliferator-activated-receptor-alpha (PPAR-alpha) gene expressions, and also increased (p < 0.05) fecal triglyceride excretions.
  • [MeSH-minor] Animals. Disease Models, Animal. Flowers / chemistry. Gene Expression / drug effects. Humans. Lipid Metabolism / drug effects. Male. PPAR alpha / genetics. PPAR alpha / metabolism. Polyphenols. Random Allocation. Rats. Rats, Sprague-Dawley. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088600.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Flavonoids; 0 / Hypolipidemic Agents; 0 / PPAR alpha; 0 / Phenols; 0 / Plant Extracts; 0 / Polyphenols; 0 / Triglycerides
  •  go-up   go-down


40. Kumar SA, Sudhahar V, Varalakshmi P: Oxidative renal injury and lipoprotein oxidation in hypercholesterolemic atherogenesis: Role of eicosapentaenoate-lipoate (EPA-LA) derivative. Prostaglandins Leukot Essent Fatty Acids; 2006 Jul;75(1):25-31
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present work is to evaluate the effects of eicosapentaenoic acid (EPA), DL alpha-lipoic acid (LA) and eicosapentaenoate-lipoate derivative (EPA-LA) in controlling the atherogenic disturbances.
  • HCD) for 30 days.
  • Abnormal increase in the levels of reactive oxygen species, 3-nitrotyrosine, malondialdehyde and protein carbonyl as well as an elevation in the activities of xanthine oxidase, lactate dehydrogenase, alkaline phosphatase and acid phosphatase was observed in renal tissue of HCD fed rats.
  • HCD fed rats also showed an increased susceptibility of the apo B-containing lipoproteins to in vitro oxidation.
  • However, the combined derivative EPA-LA almost ameliorated the hypercholesterolemic-oxidative changes in the HCD fed rats.
  • [MeSH-major] Atherosclerosis / drug therapy. Eicosapentaenoic Acid / analogs & derivatives. Hypercholesterolemia / drug therapy. Kidney Diseases / etiology. Lipoproteins / metabolism. Thioctic Acid / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737804.001).
  • [ISSN] 0952-3278
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Lipoproteins; 0 / eicosapentaenoate-lipoate; 73Y7P0K73Y / Thioctic Acid; AAN7QOV9EA / Eicosapentaenoic Acid
  •  go-up   go-down


41. Hubácek JA, Bobková D, Bohuslavová R, Poledne R: Differences in expression of cholesterol 7alpha-hydroxylase between PHHC and Wistar rats. Folia Biol (Praha); 2008;54(1):18-23
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The animals were fed standard laboratory diet (CD) or control diet containing 5% fat and 2% cholesterol (HCD) for two weeks.
  • Although the basal cholesterolemia in PHHC was similar to controls (1.80 +/- 0.48 and 1.52 +/- 0.39 mmol/l, respectively), it rose in rats fed on HCD to 9.81 +/- 1.65 mmol/l in PHHC rats and only to 2.19 +/- 0.41 mmol/l in controls.
  • In controls on HCD, cyp7A1 gene expression increased almost 4-fold immediately on the first day and achieved up to approximately 20-multiple basal expression in the end of the feeding period.
  • Compared to the controls, after switching to HCD the cyp7A1 gene expression in PHHC rats did not change dramatically.
  • [MeSH-major] Cholesterol 7-alpha-Hydroxylase / genetics. Cholesterol 7-alpha-Hydroxylase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226361.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Lipoproteins; 0 / Nucleic Acids; 97C5T2UQ7J / Cholesterol; EC 1.14.13.17 / Cholesterol 7-alpha-Hydroxylase
  •  go-up   go-down


42. Kumar SA, Sudhahar V, Varalakshmi P: Protective role of eicosapentaenoate-lipoate (EPA-LA) derivative in combating oxidative hepatocellular injury in hypercholesterolemic atherogenesis. Atherosclerosis; 2006 Nov;189(1):115-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study is to evaluate the effect of eicosapentaenoic acid (EPA), dl-alpha-lipoic acid (LA) and eicosapentaenoate-lipoate (EPA-LA) derivative on the atherogenic disturbances in hypercholesterolemic atherogenic animals.
  • HCD) for 30 days, among which, three groups of rats were also treated with either EPA (35 mg/kg body weight/day, oral gavage), LA (20 mg/kg body weight/day, oral gavage) or EPA-LA derivative (50 mg/kg body weight/day, oral gavage) commencing from 16th day of the experimental period.
  • Abnormal increases in the levels of malondialdehyde, protein carbonyl and 8-hydroxy-2-deoxyguanosine, as well as depressed antioxidants status, were observed in hepatic tissue of HCD fed rats.
  • HCD induced abnormal elevation in the activities of hepatic lactate dehydrogenase, aminotransferases and alkaline phosphatase (ALP) and was accompanied by increased hepatic cholesterol level and altered fatty changes in the histology of liver.
  • However, the combined derivative EPA-LA almost ameliorated the hypercholesterolemic-oxidative changes in the HCD fed rats.
  • [MeSH-minor] Animals. Cholesterol / metabolism. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Disease Models, Animal. L-Lactate Dehydrogenase / metabolism. Male. Rats. Rats, Wistar. Superoxide Dismutase / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458314.001).
  • [ISSN] 0021-9150
  • [Journal-full-title] Atherosclerosis
  • [ISO-abbreviation] Atherosclerosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / eicosapentaenoate-lipoate; 73Y7P0K73Y / Thioctic Acid; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; 97C5T2UQ7J / Cholesterol; AAN7QOV9EA / Eicosapentaenoic Acid; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.15.1.1 / Superoxide Dismutase; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


43. Buse C, Altmann F, Amann B, Hauck SM, Poulsen Nautrup C, Ueffing M, Stangassinger M, Deeg CA: Discovering novel targets for autoantibodies in dilated cardiomyopathy. Electrophoresis; 2008 Mar;29(6):1325-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since DCM is a fatal disorder with rapid aggravation and is the leading cause of heart transplantation, further insights into disease pathogenesis are needed.
  • Recent studies have separated the pathogenic capacity of autoantibodies and initial clinical trials removing such autoantibodies via immunoadsorption have been promising.
  • With this method, we detected five potentially DCM-related autoantigens which were identified by MS as being: myosin heavy chain cardiac muscle alpha isoform, alpha cardiac actin, mitochondrial aconitate hydratase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and brain glycogen phosphorylase (GPBB).
  • The recovery of two known DCM autoantigens (myosin heavy chain and alpha cardiac actin) and the discovery of three novel autoantigens (mitochondrial aconitate hydratase, GADPH, and GPBB) underscore the efficacy of this experimental method and the significance of the spontaneous canine DCM model.
  • [MeSH-major] Autoantibodies / immunology. Autoantigens / analysis. Cardiomyopathy, Dilated / immunology. Cardiomyopathy, Dilated / veterinary. Dog Diseases / immunology
  • [MeSH-minor] Aconitate Hydratase / immunology. Actins / immunology. Animals. Blotting, Western / methods. Dogs. Electrophoresis, Gel, Two-Dimensional / methods. Glyceraldehyde-3-Phosphate Dehydrogenases / immunology. Glycogen Phosphorylase, Brain Form / immunology. Ventricular Myosins / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288668.001).
  • [ISSN] 0173-0835
  • [Journal-full-title] Electrophoresis
  • [ISO-abbreviation] Electrophoresis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Autoantibodies; 0 / Autoantigens; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 2.4.1.- / Glycogen Phosphorylase, Brain Form; EC 3.6.1.- / Ventricular Myosins; EC 4.2.1.3 / Aconitate Hydratase
  •  go-up   go-down


44. Huang H, Liu T, Rose JL, Stevens RL, Hoyt DG: Sensitivity of mice to lipopolysaccharide is increased by a high saturated fat and cholesterol diet. J Inflamm (Lond); 2007;4:22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It was hypothesized that a pro-atherogenic, high saturated fat and cholesterol diet (HCD) would increase the inflammatory response to E. coli endotoxin (LPS) and increase its concentration in plasma after administration to mice.
  • METHODS: C57Bl/6 mice were fed a HCD or a control diet (CD) for 4 weeks, and then treated with saline, 0.5, 1 or 2 mg LPS/kg, ip.
  • Liver injury (alanine:2-oxoglutarate aminotransferase and aspartate aminotransferase, collagen staining), circulating cytokines (tumor necrosis factor-alpha, interleukin-6 and interferon-gamma), factors that can bind LPS (serum amyloid A, apolipoprotein A1, LPS binding protein, and CD14), and plasma levels of LPS were measured.
  • RESULTS: Two mg LPS/kg killed 100% of mice fed HCD within 5 d, while no mice fed CD died.
  • HCD increased plasma alanine:2-oxoglutarate aminotransferase and aspartate aminotransferase, and the enzymes were increased more by LPS in HCD than CD mice.
  • Induction of plasma tumor necrosis factor-alpha, interleukin-6, and interferon-gamma by LPS was greater with HCD than CD.
  • Hepatic VCAM-1 and iNOS protein and mRNA were induced by LPS more in mice fed HCD than CD.
  • Tyrosine phosphorylation of signal transducer and activator of transcription-1 caused by LPS was prolonged in HCD compared with CD mice.
  • Despite the hepatic effects of HCD, diet had no effect on the LPS plasma concentration-time profile.
  • HCD alone did not affect circulating levels of plasma apolipoprotein A1 or LPS binding protein.
  • However, plasma concentrations of serum amyloid A and CD14, and hepatic toll-like receptor-4 mRNA were increased in mice fed HCD.
  • CONCLUSION: HCD increased the sensitivity of mice to LPS without affecting its plasma level.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 2004 Sep 29;340(1):99-109 [15556298.001]
  • [Cites] Am J Clin Pathol. 1960 Oct;34:381-98 [13713438.001]
  • [Cites] Shock. 2006 Sep;26(3):311-5 [16912658.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):342-74 [16968945.001]
  • [Cites] Intensive Care Med. 2007 Jan;33(1):13-24 [17093985.001]
  • [Cites] J Med. 1979;10(1-2):35-48 [290725.001]
  • [Cites] Infect Immun. 1978 Aug;21(2):448-57 [689731.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Shock. 2001 Jul;16(1):44-50 [11442315.001]
  • [Cites] Trends Cell Biol. 2001 Sep;11(9):372-7 [11514191.001]
  • [Cites] Circulation. 2002 Mar 12;105(10):1158-61 [11889007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8043-7 [12060750.001]
  • [Cites] J Endotoxin Res. 2003;9(2):113-8 [12803885.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42774-84 [12923166.001]
  • [Cites] Proteomics. 2004 Feb;4(2):514-23 [14760724.001]
  • [Cites] Mol Pharmacol. 2004 Aug;66(2):302-11 [15266021.001]
  • [Cites] J Endotoxin Res. 2005;11(4):225-9 [16176659.001]
  • [Cites] J Interferon Cytokine Res. 2006 Feb;26(2):101-7 [16487030.001]
  • [Cites] FASEB J. 2006 Oct;20(12):2162-4 [16935938.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4880-7 [16982930.001]
  • [Cites] J Gastroenterol. 2006 Oct;41(10):971-80 [17096066.001]
  • [Cites] Circ Res. 2007 Jun 8;100(11):1589-96 [17478729.001]
  • [Cites] J Med. 1979;10(1-2):49-64 [314965.001]
  • [Cites] Infect Immun. 1979 Nov;26(2):658-67 [317596.001]
  • [Cites] J Nutr. 1977 Jul;107(7):1340-8 [874577.001]
  • [Cites] J Nutr. 1992 Feb;122(2):294-305 [1732470.001]
  • [Cites] Infect Immun. 1990 Apr;58(4):935-7 [2180825.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):696-702 [2394827.001]
  • [Cites] Ann N Y Acad Sci. 1989;557:310-5; discussion 315-6 [2472091.001]
  • [Cites] Prog Clin Biol Res. 1985;189:181-96 [4048203.001]
  • [Cites] Infect Immun. 1973 Jul;8(1):105-9 [4198100.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1779-84 [7684434.001]
  • [Cites] J Pharmacol Exp Ther. 1995 Feb;272(2):604-11 [7853173.001]
  • [Cites] Immunol Today. 1994 Feb;15(2):81-8 [8155266.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12040-4 [8265667.001]
  • [Cites] J Leukoc Biol. 1996 Apr;59(4):489-93 [8613694.001]
  • [Cites] Circ Res. 1997 Aug;81(2):274-81 [9242189.001]
  • [Cites] Am J Reprod Immunol. 1997 Jul;38(1):46-54 [9266010.001]
  • [Cites] Circ Res. 1997 Dec;81(6):911-21 [9400371.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Jun;161(6):1781-5 [10852744.001]
  • [Cites] Atherosclerosis. 2001 Jan;154(1):113-21 [11137089.001]
  • [Cites] Pathobiology. 1991;59(6):378-83 [1930690.001]
  • [Cites] Adv Surg. 1990;23:21-56 [2403458.001]
  • [Cites] Immunobiology. 1987 May;174(3):253-65 [3623605.001]
  • [Cites] Clin Exp Immunol. 1995 Aug;101(2):357-61 [7648721.001]
  • [Cites] Infect Immun. 1995 May;63(5):2041-6 [7729918.001]
  • [Cites] Eur Heart J. 1993 Dec;14 Suppl K:125-9 [8131781.001]
  • [Cites] Arch Surg. 1994 Feb;129(2):193-7 [8304830.001]
  • [Cites] J Exp Med. 1996 Nov 1;184(5):1601-8 [8920850.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 1):C1506-15 [9374635.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Nov;19(11):2776-81 [10559025.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1819-24 [11106554.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):485-93 [11489942.001]
  • [Cites] Circulation. 2001 Dec 18;104(25):3103-8 [11748108.001]
  • [Cites] J Surg Res. 2002 Jul;106(1):188-95 [12127825.001]
  • [Cites] Clin Microbiol Rev. 2003 Jul;16(3):379-414 [12857774.001]
  • [Cites] J Endotoxin Res. 2005;11(2):97-103 [15949136.001]
  • (PMID = 17997851.001).
  • [ISSN] 1476-9255
  • [Journal-full-title] Journal of inflammation (London, England)
  • [ISO-abbreviation] J Inflamm (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2186306
  •  go-up   go-down


45. Chennaoui M, Drogou C, Guezennec CY, Gomez-Merino D: Influence of a high carbohydrate diet on the functional activity of 5-HT1B/1D receptors on human peripheral blood lymphocytes during intense military training. Eur Cytokine Netw; 2006 Mar;17(1):67-74
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty two male soldiers (mean age: 21 +/- 2 years) were randomly assigned to two groups and received either 3200 kcal/24 h [13440 kJ; habitual diet group (HD)] or 4200 kcal/24 h [17640 kJ, high carbohydrate diet group (HCD)] by adding 1000 kcal (4200 kJ) of fruit jelly to the HD.
  • The results of [35S] GTPgammaS binding assays showed that h5-HT1B/1D receptors were desensitized after the training program in the HD group, whereas no change was observed between the beginning and the end of the military training in the HCD group [(HD : IC50 = 100 +/- 14 nM to 544 +/- 178 nM; n = 16) and (HCD: IC50 = 68 +/- 14 nM to 101 +/- 22 nM; n = 16)].
  • Serum cortisol was only significantly increased after the commando training in the HD group (from 532.2 +/- 30 to 642 +/- 45 nmol.L(-1), p < 0.05), whereas values were not significantly changed in the HCD group (441 +/- 31 to 502 +/- 40 nmol.L(-1)).
  • No changes were observed in IL-10, TNF-alpha and IFN-gamma levels after the training program in either group.

  • MedlinePlus Health Information. consumer health - Carbohydrates.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613765.001).
  • [ISSN] 1148-5493
  • [Journal-full-title] European cytokine network
  • [ISO-abbreviation] Eur. Cytokine Netw.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cytokines; 0 / Dietary Carbohydrates; 0 / Receptor, Serotonin, 5-HT1B; 0 / Receptor, Serotonin, 5-HT1D; 37589-80-3 / Guanosine 5'-O-(3-Thiotriphosphate); WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


46. Kumar SA, Sudhahar V, Varalakshmi P: Attenuation of serum lipid abnormalities and cardiac oxidative stress by eicosapentaenoate-lipoate (EPA-LA) derivative in experimental hypercholesterolemia. Clin Chim Acta; 2005 May;355(1-2):197-204
MedlinePlus Health Information. consumer health - Cholesterol.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dietary cholesterol plays an important role in development of atherogenesis and cardiovascular disease.
  • The effects of eicosapentaenoic acid (EPA), dl-alpha-lipoic acid (LA) and eicosapentaenoate-lipoate derivative (EPA-LA) were tested for their efficacy in controlling the atherogenic disturbances.
  • HCD) for 30 days.
  • RESULTS: HCD induced abnormal increase in lipid peroxidation and serum cholesterol, triglyceride, LDL and VLDL, and a decreased HDL concentration.
  • Altered activity of cardiac and serum creatine kinase, accompanied by a depressed cardiac enzymatic and nonenzymatic antioxidants defense system were observed in HCD fed rats.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820496.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 0 / eicosapentaenoate-lipoate; 73Y7P0K73Y / Thioctic Acid; AAN7QOV9EA / Eicosapentaenoic Acid
  •  go-up   go-down


47. Ramadeen A, Laurent G, dos Santos CC, Hu X, Connelly KA, Holub BJ, Mangat I, Dorian P: n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. Heart Rhythm; 2010 Apr;7(4):520-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results were confirmed with quantitative real-time polymerase chain reaction (RT-PCR) and histology on all 36 dogs.
  • RESULTS: Microarray or quantitative RT-PCR results showed that SAVP-No PUFAs dogs had significantly increased mRNA levels of protein kinase B (Akt), epidermal growth factor (EGF), JAM3, myosin heavy chain alpha (MHCalpha), and CD99 and significantly decreased levels of Smad6 compared with CTRL dogs.
  • [MeSH-minor] Animals. Disease Models, Animal. Dogs. Fibrosis / genetics. Gene Expression / drug effects. Hypertrophy / genetics. Stress, Mechanical


48. Makino N, Toyofuku T, Takegahara N, Takamatsu H, Okuno T, Nakagawa Y, Kang S, Nojima S, Hori M, Kikutani H, Kumanogoh A: Involvement of Sema4A in the progression of experimental autoimmune myocarditis. FEBS Lett; 2008 Nov 26;582(28):3935-40
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dendritic cells pulsed with myosin heavy chain-alpha peptides induced severe myocarditis in wild-type mice, but not in Sema4A-deficient mice.
  • In adoptive transfer experiments, CD4+ T-cells from wild-type mice induced severe myocarditis, while CD4+ T-cells from Sema4A-deficient mice exhibited considerably attenuated myocarditis.
  • [MeSH-major] Autoimmune Diseases / immunology. CD4-Positive T-Lymphocytes / immunology. Myocarditis / immunology. Semaphorins / physiology
  • [MeSH-minor] Adoptive Transfer. Animals. Cell Differentiation / genetics. Disease Models, Animal. Disease Progression. Disease Susceptibility. Lymphocyte Activation / genetics. Mice. Mice, Inbred BALB C. Mice, Knockout. Mice, SCID. Th1 Cells / immunology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18977352.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Sema4A protein, mouse; 0 / Semaphorins
  •  go-up   go-down


49. Du MQ: MALT lymphoma : recent advances in aetiology and molecular genetics. J Clin Exp Hematop; 2007 Nov;47(2):31-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MALT lymphoma : recent advances in aetiology and molecular genetics.
  • Mucosa-associated lymphoid tissue (MALT) lymphoma is a common low grade B-cell lymphoma arising from a background of chronic inflammatory disease at a number of mucosal sites.
  • Those originating in the stomach are causatively linked to Helicobacter pylori infection and eradication of the bacterium with antibiotics leads to long-term complete regression of the lymphoma in aproximately 70% of cases.
  • Now, there is further evidence of linking Campylobacter jejuni, Borrelia burgdorferi and Chlamydia psittaci infection with immunoproliferative small intestine disease, MALT lymphoma of the skin and ocular adnexa respectively. t(11;18)/API2-MALT1, t(1;14)/IGH-BCL10, t(14;18)/IGH-MALT1 and t(3;14)/IGH-FOXP1 occur at considerably variable incidences in MALT lymphomas of different sites.
  • The first three chromosome translocations are specifically associated with the MALT lymphoma entity and the oncogenic products of these translocations have been shown to target a common molecular pathway, i.e. the nuclear factor-kappaB pathway.
  • Here, I review the recent advances in our understanding of the association of microbial pathogens with MALT lymphoma of various sites and the molecular genetics underlying the lymphoma development.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040143.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 99
  •  go-up   go-down


50. Jin HO, An S, Lee HC, Woo SH, Seo SK, Choe TB, Yoo DH, Lee SB, Um HD, Lee SJ, Park MJ, Kim JI, Hong SI, Rhee CH, Park IC: Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell Signal; 2007 Jul;19(7):1393-403
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we demonstrated that the expression of Redd1 in response to hypoxia (1% O(2)), hypoxia-mimetic agent, cobalt chloride (CoCl(2)) and high cell density (HCD) requires coactivation of HIF-1alpha and Sp1.
  • CoCl(2) and HCD induced the activation of HIF-1alpha and Sp1 in HeLa cells, and siRNAs targeting HIF-1alpha and Sp1 abrogated Redd1 expression.
  • Inhibition of phosphatidylinositol 3-kinase (PI3K) by LY294002 and by a dominant-negative PI3K mutant reduced the expression of Redd1 and activation of HIF-1alpha and Sp1 by CoCl(2) and HCD.
  • Also, suppression of Akt activation blocked the expression of Redd1 and the activation of HIF-1alpha and Sp1 by CoCl(2) and HCD.
  • These results demonstrate that hypoxic condition-and HCD-induced expression of Redd1 is mediated by coactivation of Sp1 and HIF-1alpha downstream of the PI3K/Akt signaling pathway.
  • [MeSH-major] Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. Sp1 Transcription Factor / metabolism. Transcription Factors / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17307335.001).
  • [ISSN] 0898-6568
  • [Journal-full-title] Cellular signalling
  • [ISO-abbreviation] Cell. Signal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DDIT4 protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Sp1 Transcription Factor; 0 / Transcription Factors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


51. Suarez F, Lortholary O, Hermine O, Lecuit M: Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood; 2006 Apr 15;107(8):3034-44
MedlinePlus Health Information. consumer health - Bacterial Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation.
  • Non-Hodgkin lymphomas develop from nodal and extranodal lymphoid tissues.
  • A distinct subset of extranodal lymphomas arising from B cells of the marginal zone (MZ) of mucosa-associated lymphoid tissue (MALT) or spleen has been individualized.
  • Growing evidence indicates that MZ lymphomas are associated with chronic antigenic stimulation by microbial pathogens and/or autoantigens.
  • The list of microbial species associated with MZ lymphoproliferations has grown longer with molecular investigations and now comprises at least 5 distinct members: H. pylori, C. jejuni, B. burgdorferi, C. psittaci, and hepatitis C virus (HCV), which have been associated with gastric lymphoma, immunoproliferative small intestinal disease, cutaneous lymphoma, ocular lymphoma, and spleen lymphoma, respectively.
  • [MeSH-major] Antigen Presentation / immunology. Antigens, Bacterial / immunology. B-Lymphocytes / immunology. Bacterial Infections / immunology. Cell Proliferation. Lymphoma, B-Cell / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397126.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial
  • [Number-of-references] 162
  •  go-up   go-down


52. Stratigos P, Kouskos E, Kouroglou M, Chrisafis I, Fois L, Mavrogiorgis A, Axiotis E, Zamtrakis S: Emergency pancreatoduodenectomy (whipple procedure) for massive upper gastrointestinal bleeding caused by a diffuse B-cell lymphoma of the duodenum: report of a case. Surg Today; 2007;37(8):680-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergency pancreatoduodenectomy (whipple procedure) for massive upper gastrointestinal bleeding caused by a diffuse B-cell lymphoma of the duodenum: report of a case.
  • We herein report a rare case of a massive upper gastrointestinal (GI) bleeding, caused by high-grade diffuse B-cell lymphoma of the duodenum, secondary to immunoproliferative small intestinal disease (IPSID) and treated with an emergency partial pancreatoduodenectomy.
  • An urgent abdominal ultrasound raised the suspicion of a large, possibly bleeding, neoplasm of the duodenum, which was finally confirmed by abdominal computed tomography.
  • Histologically, the tumor was a high-grade B-cell lymphoma of the duodenum.
  • The nearby small intestinal mucosa was suggestive of IPSID.
  • A massive upper GI hemorrhage from a high-grade B-cell non-Hodgkin lymphoma of the duodenum, which develops secondary to IPSID, is a very rare clinical demonstration of this disease.
  • [MeSH-major] Duodenal Neoplasms / complications. Emergency Treatment. Gastrointestinal Hemorrhage / surgery. Lymphoma, B-Cell / complications. Pancreaticoduodenectomy / methods. Upper Gastrointestinal Tract / surgery
  • [MeSH-minor] Humans. Immunoproliferative Small Intestinal Disease

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17643214.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian BR, Gura KM, Nose V, Zauscher B, Moses M, Puder M: Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol; 2006 Dec;291(6):G1011-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model.
  • Steatosis is a prominent feature of nonalcoholic fatty liver disease and a potential promoter of inflammation.
  • Matrix metalloproteinase (MMP) inhibitors protect mice from lethal TNF-alpha induced liver injury.
  • We hypothesized that Marimastat, a broad-spectrum MMP and TNF-alpha converting enzyme (TACE) inhibitor, might modulate this injury through interruption of inflammatory pathways.
  • Triglyceride and phospholipid levels (liver, serum) and fatty acid profiles were used to assess essential fatty acid status and de novo lipogenesis as mechanisms for hepatic steatosis.
  • Mice receiving a fat-free, high-carbohydrate diet (HCD) for 19 days developed severe fatty liver infiltration, demonstrated by histology, magnetic resonance spectroscopy, and elevated liver function tests.
  • Animals receiving HCD plus Marimastat (HCD+MAR) were comparable to control animals.
  • Increased tissue levels of peroxisome proliferator activated receptor-alpha (PPAR-alpha), higher levels of serum IL-6, and decreased levels of serum TNF-alpha receptor II were also seen in the HCD+MAR group compared with HCD-only.
  • In addition, there was increased phosphorylation, and likely activation, of PPAR-alpha in the HCD+MAR group.
  • PPAR-alpha is a transcription factor involved in beta-oxidation of fatty acids, and IL-6 is a hepatoprotective cytokine.
  • Liver triglyceride levels were higher and serum triglyceride and phospholipid levels lower with HCD-only but improved with Marimastat treatment.
  • HCD-only and HCD+MAR groups were essential fatty acid deficient and had elevated rates of de novo lipogenesis.
  • This may be related to increased expression and activation of PPAR-alpha or IL-6, respectively.

  • MedlinePlus Health Information. consumer health - Carbohydrates.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844679.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK040561; None / None / / P30 DK040561-11; United States / NCI NIH HHS / CA / CA-83106; United States / NIDDK NIH HHS / DK / DK-065298; United States / NIDDK NIH HHS / DK / P30 DK040561-11; United States / NIDDK NIH HHS / DK / DK-069621-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Carbohydrates; 0 / Hydroxamic Acids; 0 / Interleukin-6; 0 / Matrix Metalloproteinase Inhibitors; 0 / PPAR alpha; D5EQV23TDS / marimastat
  •  go-up   go-down


54. Qiu Y, Yanase T, Hu H, Tanaka T, Nishi Y, Liu M, Sueishi K, Sawamura T, Nawata H: Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Endocrinology; 2010 Jul;151(7):3307-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2) noncastrated group with high-cholesterol diet (HCD) (n = 10);.
  • 3) castrated group with HCD plus sc placebo pellet (n = 11); and 4) castrated group with HCD plus sc 150 mg DHT pellet (n = 12).
  • After castration or sham operation, the rabbits were fed the HCD for 8 wk, and plaque areas were assessed in the entire aorta.
  • The HCD-induced increase in plaque area, which was most aggravated in the castration plus placebo group, was attenuated in the castration plus DHT group.
  • Microscopic examination of the proximal descending aorta revealed that DHT significantly reduced HCD-induced foam cell formation, which was mostly composed of macrophages in the intima layer, compared with the placebo group.
  • In cultured macrophages prepared from male wild-type mice that express the androgen receptor (AR), 1 x 10(-8) m and 1 x 10(-9) m DHT inhibited the formation of foam cells induced by oxidized low-density lipoprotein.
  • [MeSH-minor] Animals. Aorta, Thoracic / cytology. Body Weight. Cells, Cultured. Cholesterol, Dietary. Interleukin-1alpha / genetics. Interleukin-6 / genetics. Lipids / blood. Male. Mice. Polymerase Chain Reaction. Rabbits. Random Allocation. Scavenger Receptors, Class E / genetics. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427482.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholesterol, Dietary; 0 / Interleukin-1alpha; 0 / Interleukin-6; 0 / Lipids; 0 / Scavenger Receptors, Class E; 0 / Tumor Necrosis Factor-alpha; 08J2K08A3Y / Dihydrotestosterone
  •  go-up   go-down


55. Cahill MG, Caprioli G, Vittori S, James KJ: Elucidation of the mass fragmentation pathways of potato glycoalkaloids and aglycons using Orbitrap mass spectrometry. J Mass Spectrom; 2010 Sep;45(9):1019-25
Hazardous Substances Data Bank. SOLANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, higher energy collisional-induced dissociation (HCD) mass spectra were generated for these toxins at a high resolution setting [100,000 FWHM (full width at half maximum)] using the Orbitrap.
  • This hybrid mass spectrometry instrumentation was exploited to produce MS(3) spectra by selecting MS(2) product ions, generated using LIT MS, and fragmentation using HCD.

  • Hazardous Substances Data Bank. SOLASODINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 John Wiley & Sons, Ltd.
  • (PMID = 20641001.001).
  • [ISSN] 1096-9888
  • [Journal-full-title] Journal of mass spectrometry : JMS
  • [ISO-abbreviation] J Mass Spectrom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Solanaceous Alkaloids; 0 / Toxins, Biological; 0 / alpha-solanine; 20562-02-1 / Solanine; 20562-03-2 / alpha-chaconine; L40Y453Y96 / solasodine; VG66W0726Y / demissidine
  •  go-up   go-down


56. Phanstiel D, Zhang Y, Marto JA, Coon JJ: Peptide and protein quantification using iTRAQ with electron transfer dissociation. J Am Soc Mass Spectrom; 2008 Sep;19(9):1255-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate here that ETD of iTRAQ labeled peptides produces c- and z-type fragment ions as well as reporter ions that are unique from those produced by CAD.
  • These experiments revealed that ETD cleavage of the N-C(alpha) bond of the iTRAQ tag results in fragment ions that could be used for quantification.
  • Synthetic peptide work demonstrates that these fragment ions provide up to three channels of quantification and that the quality is similar to that provided by beam-type CAD.
  • Protein standards were used to evaluate peptide and protein quantification of iTRAQ labeling in conjunction with ETD, beam-type CAD, and pulsed Q dissociation (PQD) on a hybrid ion trap-orbitrap mass spectrometer.
  • Approximately 36%, 8%, and 16% of scans identified fall below this threshold for ETD, HCD, and PQD, respectively.
  • At the protein level, average errors were 2.3%, 1.7%, and 3.6% for ETD, HCD, and PQD, respectively.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2007 May 15;79(10):3525-34 [17441688.001]
  • [Cites] Expert Rev Proteomics. 2004 Oct;1(3):317-26 [15966828.001]
  • [Cites] Anal Bioanal Chem. 2007 Oct;389(4):1017-31 [17668192.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4230-44 [17900180.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4200-9 [17902639.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1942-51 [17673454.001]
  • [Cites] Anal Chem. 2007 Dec 15;79(24):9243-52 [18020370.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3127-36 [18613715.001]
  • [Cites] Proteomics. 2007 Apr;7(7):1150-63 [17390297.001]
  • [Cites] Rapid Commun Mass Spectrom. 2000;14(14):1226-32 [10918372.001]
  • [Cites] Anal Chem. 2001 Jun 1;73(11):2578-86 [11403303.001]
  • [Cites] Anal Chem. 2001 Jul 1;73(13):2836-42 [11467524.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):885-90 [11798155.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1265-72 [15958392.001]
  • [Cites] Nat Chem Biol. 2005 Oct;1(5):252-62 [16408053.001]
  • [Cites] Science. 2006 Apr 14;312(5771):212-7 [16614208.001]
  • [Cites] Anal Chem. 2006 Jun 1;78(11):3788-93 [16737238.001]
  • [Cites] J Proteome Res. 2006 Aug;5(8):2009-18 [16889424.001]
  • [Cites] Proteomics. 2006 Oct;6(20):5418-34 [16972287.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1764(12):1811-22 [17118725.001]
  • [Cites] Anal Chem. 2007 Jan 15;79(2):477-85 [17222010.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2199-204 [17287340.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2193-8 [17287358.001]
  • [Cites] Nat Methods. 2007 Mar;4(3):207-14 [17327847.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):512-5 [11981568.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Methods. 2003 Feb;29(2):124-30 [12606218.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] J Proteome Res. 2003 Jan-Feb;2(1):43-50 [12643542.001]
  • [Cites] Eur J Mass Spectrom (Chichester, Eng). 2004;10(3):335-48 [15187293.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9528-33 [15210983.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):350-63 [15253416.001]
  • [Cites] Anal Chem. 2004 Sep 1;76(17):4951-9 [15373428.001]
  • [Cites] J Proteome Res. 2004 Sep-Oct;3(5):958-64 [15473683.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6591-6 [10359756.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):628-32 [15822944.001]
  • [Cites] Nat Methods. 2007 Sep;4(9):709-12 [17721543.001]
  • (PMID = 18620867.001).
  • [ISSN] 1044-0305
  • [Journal-full-title] Journal of the American Society for Mass Spectrometry
  • [ISO-abbreviation] J. Am. Soc. Mass Spectrom.
  • [Language] ENG
  • [Grant] United States / NHGRI NIH HHS / HG / HG002760-02; United States / NHGRI NIH HHS / HG / T32 HG002760-05; United States / NHGRI NIH HHS / HG / 5T32HG002760; United States / NIGMS NIH HHS / GM / R01 GM080148-02; United States / NHGRI NIH HHS / HG / T32 HG002760-02; United States / NHGRI NIH HHS / HG / T32 HG002760-01; None / None / / T32 HG002760-05; United States / NHGRI NIH HHS / HG / HG002760-03; United States / NHGRI NIH HHS / HG / HG002760-06; United States / NHGRI NIH HHS / HG / T32 HG002760-06; United States / NIGMS NIH HHS / GM / R01 GM080148-01A1; United States / NHGRI NIH HHS / HG / T32 HG002760; United States / NIGMS NIH HHS / GM / 1R01GM080148; United States / NHGRI NIH HHS / HG / T32 HG002760-03; United States / NIGMS NIH HHS / GM / R01 GM080148; None / None / / T32 HG002760-04; United States / NHGRI NIH HHS / HG / T32 HG002760-04; United States / NHGRI NIH HHS / HG / HG002760-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides
  • [Other-IDs] NLM/ NIHMS70266; NLM/ PMC2562465
  •  go-up   go-down


57. Guo L, Kuroda N, Nakayama H, Miyazaki E, Hayashi Y, Toi M, Hiroi M, Enzan H: Cytokeratin-positive subserosal myofibroblasts in gastroduodenal ulcer; another type of myofibroblasts. Histol Histopathol; 2006 07;21(7):697-704
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin-positive subserosal myofibroblasts in gastroduodenal ulcer; another type of myofibroblasts.
  • To investigate the distribution and origin of alpha-smooth muscle actin (ASMA)-positive stromal cells in the perforation of human gastroduodenal ulcers.
  • Perforative lesions of 24 surgically resected gastroduodenal ulcers were examined immunohistochemically for ASMA, HCD, CD34, CD31, CAM5.2 and HMW-CK, and double staining of ASMA and CAM5.2 was also performed.
  • The cytokeratin-positive subserosal myofibroblastic cell in human gastroduodenal ulcer is a novel type of myofibroblast.
  • [MeSH-minor] Actins / metabolism. Antigens, CD34 / metabolism. Biomarkers / metabolism. Collagen Type I / genetics. Collagen Type I / metabolism. Humans. Immunoenzyme Techniques. In Situ Hybridization. Peptic Ulcer Perforation / complications. Peptic Ulcer Perforation / metabolism. Peptic Ulcer Perforation / pathology. RNA, Messenger / analysis. Serous Membrane / metabolism. Serous Membrane / pathology. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Peptic Ulcer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598668.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Collagen Type I; 0 / RNA, Messenger; 68238-35-7 / Keratins
  •  go-up   go-down


58. Shiota G: Loss of function of retinoic acid in liver leads to steatohepatitis and liver tumor: A NASH animal model. Hepatol Res; 2005 Oct;33(2):155-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To explore the role of retinoic acid (RA) in liver, we developed transgenic mice expressing retinoic acid receptor alpha dominant negative form (RARE) in hepatocytes using by albumin promoter and enhancer.
  • Mitochondrial beta-oxidation activity of fatty acids and expression of its related enzymes including VLCAD, LCAD and HCD were down-regulated.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202648.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


59. Landolsi A, Chabchoub I, Limem S, Gharbi O, Chaafai R, Hochlef M, Fatma LB, Trimech M, Krifa A, Ajmi S, Mokni M, Hadj Hmida MB, Ahmed SB: [Primary digestive tract lymphoma in central region of Tunisia: anatomoclinical study and therapeutic results about 153 cases]. Bull Cancer; 2010 Apr;97(4):435-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary digestive tract lymphoma in central region of Tunisia: anatomoclinical study and therapeutic results about 153 cases].
  • [Transliterated title] Les lymphomes primitifs du tube digestif (LPTD) dans le centre tunisien: étude anatomoclinique et résultats thérapeutiques à propos de 153 cas.
  • Primary gastro-intestinal lymphoma (PGIL) is the most common type of extra-nodal non Hodgkin's lymphoma.
  • Their clinical and histological presentations are heterogeneous depending on the site of the lesion.
  • In our country epidemiology of the disease is unknown with IPSID being the most frequent type.
  • We report anatomo-clinical features and prognostic factors of PGIL and compare intestinal to gastric forms in our region.
  • Tumor sites were gastric (67%), intestinal (26%) and gastrointestinal (7%).
  • Abdominal pain (87%) followed by vomiting and diarrhoea (37 and 15%) were the most common symptoms.
  • Performance status (PS) < 2 was seen in 80% of patients, high grade lymphoma in 70.5% of cases and B phenotype was noted in 85%.
  • MALT lymphoma accounts for 50% of cases, and IPSID for only 5% of PGIL.
  • Only 46% of patients had surgery (14 for surgical complication, 6 for residual tumor after chemotherapy and 22 to have histological diagnosis).
  • In high grade lymphoma patients favorable prognostic factors for OS included young age < or = 60 years, PS < 2, normal serum LDH, hemoglobin > 12 g/dL, B phenotype, localised stage (IE-IIE1), anthracycline-based chemotherapy regimen, achieving complete or partial response to induction chemotherapy and no relapse.
  • In low-grade lymphoma patients, none of these factors had a significant correlation with OS: age < or = 60 years, PS < 2, stage (IE-IIE1), response to induction chemotherapy, relapse.
  • Compared to gastric lymphomas, intestinal cases occurred at a younger age, frequently with diarrhoea, weight loss, and occlusion.
  • We conclude that stomach is the main site of PGIL in our region, intestinal lymphoma is less frequent and IPSID has become rare.
  • [MeSH-major] Gastrointestinal Neoplasms. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diarrhea / etiology. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Tunisia. Vomiting / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395189.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


60. Krebs P, Kurrer MO, Kremer M, De Giuli R, Sonderegger I, Henke A, Maier R, Ludewig B: Molecular mapping of autoimmune B cell responses in experimental myocarditis. J Autoimmun; 2007 Jun;28(4):224-33
Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Screening of a heart cDNA library with sera of cardiac myosin heavy chain alpha (myhcalpha) peptide-immunized BALB/c mice revealed a strong focusing of the B cell response on the myhcalpha protein.
  • [MeSH-major] Autoantibodies / immunology. Autoimmune Diseases / immunology. B-Lymphocytes / immunology. Myocarditis / immunology. Myocardium / immunology. Myosin Heavy Chains / immunology

  • Genetic Alliance. consumer health - Myocarditis.
  • Genetic Alliance. consumer health - Autoimmune Myocarditis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17336498.001).
  • [ISSN] 0896-8411
  • [Journal-full-title] Journal of autoimmunity
  • [ISO-abbreviation] J. Autoimmun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Epitopes, B-Lymphocyte; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


61. Lecuit M, Lortholary O: [Immunoproliferative small intestinal disease associated with Campylobacter jejuni]. Med Mal Infect; 2005 Jun;35 Suppl 2:S56-8
MedlinePlus Health Information. consumer health - Campylobacter Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunoproliferative small intestinal disease associated with Campylobacter jejuni].
  • [Transliterated title] Maladie immunoproliférative de l'intestin grêle associée à Campylobacter jejuni.
  • [MeSH-major] Campylobacter Infections / complications. Intestinal Diseases / microbiology. Lymphoma, B-Cell, Marginal Zone / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15978389.001).
  • [ISSN] 0399-077X
  • [Journal-full-title] Médecine et maladies infectieuses
  • [ISO-abbreviation] Med Mal Infect
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


62. Lankarani KB, Masoompour SM, Masoompour MB, Malekzadeh R, Tabei SZ, Haghshenas M: Changing epidemiology of IPSID in Southern Iran. Gut; 2005 Feb;54(2):311-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing epidemiology of IPSID in Southern Iran.
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1968 Dec 20;162(3860):1396-7 [4177362.001]
  • [Cites] Gut. 1970 Aug;11(8):673-8 [4919259.001]
  • [Cites] Cancer. 1971 Apr;27(4):965-77 [5574084.001]
  • [Cites] IARC Sci Publ. 1991;(95):126-58 [1894318.001]
  • [Cites] Am J Dig Dis. 1977 Oct;22(10):866-73 [411371.001]
  • [Cites] N Engl J Med. 1983 Jun 9;308(23):1401-5 [6405275.001]
  • [Cites] Bull World Health Organ. 1976;54(6):615-24 [829415.001]
  • (PMID = 15647204.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774824
  •  go-up   go-down


63. Xu SQ, Fang F, Zhou H: [Immunoproliferative small intestinal disease: a case report and literature review]. Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug;9(4):389-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunoproliferative small intestinal disease: a case report and literature review].
  • [MeSH-major] Immunoproliferative Small Intestinal Disease / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706052.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin A
  •  go-up   go-down






Advertisement